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ABSTRACT 
 
The development of methods and techniques is the driving force of 
scientific research.  In this work, we described two large-scale screens in 
studying transcriptional activation and tumor suppression.   
In Part I, we studied transcriptional activation mechanisms by deriving and 
characterizing activation defective mutants.  Promoter-specific transcriptional 
activators stimulate transcription through direct interactions with one or more 
components of the transcription machinery, termed the “target”. The identification 
of direct in vivo targets of activators has been a major challenge. We perform a 
large-scale genetic screen to derive and characterize tra1 alleles that are 
selectively defective for interaction with Gal4 in vivo.  Utilizing these mutants, we 
demonstrated that Tra is an essential target for Gal4 activation, Gal4 and Tra1 
bind cooperatively at the promoter and the Gal4–Tra1 interaction occurs 
predominantly on the promoter.  In addition, we demonstrated that the Gal4-
interaction site on Tra1 is highly selective. 
In Part II, we described a functional genomics approach to discover new 
tumor suppressor genes.  A goal of contemporary cancer research is to identify 
the genes responsible for neoplastic transformation.  Cells that are immortalized 
but non-tumorigenic were stably transduced with pools of short hairpin RNAs 
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(shRNAs) and tested for their ability to form tumors in mice. ShRNAs in any 
resulting tumors were identified by sequencing to reveal candidate TSGs, which 
were then validated both experimentally and clinically by analysis of human 
tumor samples. Using this approach, we identified and validated 33 candidate 
TSGs. We found that most candidate TSGs were down-regulated in >70% of 
human lung squamous cell carcinoma (hLSCC) samples, and 17 candidate 
TSGs negatively regulate FGFR signalling pathway, and their ectopic expression 
inhibited growth of hLSCC xenografts.  Furthermore, we suggest that by 
examining at the expression level of TSGs in lung cancer patients, we can 
predict their drug responsiveness to FGFR inhibitors.  In conclusion, we have 
identified many new lung squamous cell cancer TSGs, using an experimental 
strategy that can be broadly applied to find TSGs in other tumor types. 
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PART I 
STUDYING TRANSCRIPTIONAL ACTIVATION 
MECHANISMS BY DERIVING AND CHARACTERIZING 
ACTIVATION DEFECTIVE MUTANTS 
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CHAPTER I 
GENERAL INTRODUCTION 
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1.1.1 Transcription 
Transcription is a process of copying DNA into a sequence 
complementary RNA molecule.  Messenger RNA (mRNA) is then tailored 
(splicing) and translated into a protein, which has cellular functions.  Non-coding 
RNAs function in translation or gene regulation.  Transcription is the first step of 
gene expression. 
The regulation of transcription directly influences cell viability, fitness, 
response to environment, etc.  During the transcription process, DNA sequence 
is read by RNA polymerases.  Eukaryotes have several types of RNA 
polymerases.  RNA polymerase I synthesizes ribosomal RNA (rRNAs), which are 
the RNA components of ribosome.  RNA polymerase II (Pol II) synthesizes 
mRNAs and most small nuclear RNAs (snRNAs) and microRNAs.  RNA 
polymerase III synthesizes transfer RNAs (tRNAs), rRNA 5S and other small 
RNAs.  RNA polymerase IV and V are only found in plants.  RNA Pol II is the 
most studied type of RNA polymerase, because it transcribes all the coding 
genes.  
 
1.1.2 Pol II Transcription 
In eukaryotes, transcriptional regulation mechanisms are conserved from 
single cell to multiple cell organisms.  The discovery of RNA polymerase in 1959 
by Weiss and Gladstone launched the field of transcription studies (Weiss and 
Gladstone, 1959).  Ten years later, the purification of three eukaryotic RNA 
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polymerases by Roeder and Rutter provided the foundation for the study of gene 
expression regulation (Roeder and Rutter, 1969). These purified RNA 
polymerases can initiate transcription at selected promoters in vitro with the help 
of basal or general transcription factors (GTFs). In vivo, successful promoter 
specific transcription requires additional apparatuses such as activators, 
chromatin-modification factors, elongation factors, etc.  By sequentially recruiting 
these factors, eukaryotic transcription works in multi-steps: pre-initiation complex 
(PIC) assembly, PIC activation, initiation, promoter clearance, elongation and 
termination. 
General transcription factors (GTF)?
“Basal” transcription, which only occurs in vitro, requires PIC, which 
consists of RNA Pol II and GTFs.  Core RNA Pol II has 12 subunits (Rpb1-
Rpb12).  They are structurally and functionally conserved from yeast to human.  
Pol II alone cannot recognize specific promoters without additional factors.  
“Activated” transcription, which occurs in vivo, requires additional regulatory 
molecules. GTFs include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH, named in 
the order of discovery by chromatographic elution (Matsui et al 1980).   
PIC formation 
Formation of PIC on promoter occurs in a series of ordered steps (Figure 
1.1.1): (1) TFIID recognizes of a promoter and forms the nucleus of transcription 
initiation complex; (2) TFIIB recognizes the TFIID-promoter complex and forms 
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DNA binding (DB) complex; (3) TFIIF/pol II complex is recruited to the promoter; 
(4) recruitment of TFIIE and TFIIH completes the PIC formation.   
PIC activation 
Immediately following the PIC formation is PIC activation (DNA melting), 
which form an “open” initiation complex.  Unlike other steps, DNA melting 
requires energy.  The helicase activity of ERCC3 (excision repair cross-
complementing rodent repair deficiency, complementation group 3) in TFIIH 
facilitates DNA melting of a 10bp region upstream of the start site.  TFIIE assists 
melting by stabilizing the single-stranded region near the start site. During this 
process, carboxy-terminal domain (CTD) of polymerase II is phosphorylated, 
which allows promoter clearance and elongation for synthesizing longer 
transcripts.   
Recycle of transcription factors 
PIC components will be released from Pol II in the order of TFIIB, TFIIE 
and TFIIH, and recycled for the next round of transcription initiation.  After 
transcription termination, Pol II CTD will be dephosphorylated, and recycled for 
the PIC assembly. 
 
1.1.3 Transcriptional regulation 
Transcriptional regulation is conducted at different levels: cis-regulators, 
which are DNA elements and trans-regulators, such as transcription factors, 
chromatin structures, etc.  
  6 
Trans-regulating factors 
Repressors and mechanisms.  The isolation and mechanism study of 
lac repressor by Gilbert and Ptashne proved the visionary hypothesis of 
repressor proposed by Jacob and Monod in 1961 and evidenced the existence of 
trans-acting factors that could regulate transcription by binding to the upstream 
DNA sequences (Jacob 1961, Gilbert 1966, Ptashne 1967).  Transcription 
repressors can be divided into two classes: general repressors and gene specific 
repressors.  General repressors function through interacting with the TATA-
binding protein (TBP) or preventing PIC assembly.  Gene specific repressors 
function via: (1) binding to activators, for example, Gal80 represses Gal4 function 
by binding to its activation domain,  (2) competing for activator binding sites, (3) 
interacting with transcription apparatuses, and (4) modifying chromatin by 
recruiting histone deacetylases (HDAC) to specific locations. 
Activators and mechanisms.  The existence of activators was not 
accepted until 1970 when Beckwith and Ptashne discovered and characterized 
an activator of the lac operon (Zubay et al, 1970; Emmer et al, 1970).  A single 
activator usually can activate multiple genes and a single gene can be regulated 
by multiple activators as well.  Therefore, activators regulate gene expression in 
a coordinated and combinatorial fashion.  Activators stimulate transcription by 
several mechanisms: (1) recruiting chromatin modifying complexes to the 
promoters, (2) recruiting transcription initiation apparatus to the promoters, (3) 
influencing the activity of the transcription apparatus.    
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Transcription activators have several broad classes based on their 
activation domains: proline-rich, glutamine-rich, and acidic activators.  
Mammalian proline-rich or glutamine-rich activator domains have no function in 
yeast (Ponticelli et al, 1995; Kunzler et al, 1994).  Acidic activators function in all 
eukaryotes from yeast to human.  Yeast acidic activators are modular proteins 
with two functionally and physically distinct domains.  One is specific DNA-
binding domain that reads promoter sequence.  One domain is a short acidic 
region that can recognize transcription co-factors and the interaction with co-
factor is independent on the structural complementarity (Sadowski et al, 1988). 
Cis-regulating factors 
The concept of promoter was first proposed by Ippen in 1968, and in 1971 
Eron and Block confirmed it by in vitro transcription experiments (Ippen 1968, 
Eron 1971).  The first detailed transcription factor binding sequence was 
described by Tjian in 1978 using SV40 DNA.  For most protein-coding genes, 
their promoters consist of a core promoter and transcriptional regulator binding 
sequences.  The core promoter includes the transcription start site and TATA 
box.  Transcriptional regulator binding sequences include upstream activating 
sequences (UASs), enhancers, upstream repressing sequences (URSs), and 
silencers. UASs usually refer to the activator binding elements that are close to 
the transcription start site.  Enhancers refer to the clusters of DNA binding 
sequences for transcriptional regulators distant from the start site, and it is 
independent of orientation. 
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Chromatin structure and function 
Throughout the 1960s, DNA was thought to be “naked” in a linear form, 
until 1974, Roger Kornberg presented the “nucleosome hypothesis”, in which 
eukaryotic DNA is packaged around histones to form nucleosome arrays 
(Kornberg et al, 1974).  By packaging DNA into chromatin, DNA can fit into the 
limiting confines of nucleus and be strengthened for mitosis and meiosis.  In 
addition, the chromatin structure can prevent DNA damage, control gene 
expression and DNA replication.  Chromatin consists of repeating nucleoprotein 
units named nucleosomes and linker DNA.  A nucleosome contains three parts: 
(1) nucleosome core, which is 146bp of DNA wrapped in 1.67 left-handed 
superhelical turns around the histone octamer, (2) the linker DNA connects 
adjacent histone octamers, (3) linker histone, H1, that binds the linker DNA and 
nucleosome core, and forms the exit/entry of the DNA strand on the nucleosome.  
Transcription inhibition caused by packaging promoters in nucleosomes was 
found in vitro by Kornberg and colleagues in 1987, and was not accepted until it 
is proven in vivo by Han and Grunstein in 1988 (Knezetic and luse, 1986; Lorch 
et al., 1987; Han and Grunstein, 1988).  Histone-DNA contact and higher order of 
chromatin structures can restrict access of transcription factors to the promoter 
elements.  Disruption of nucleosome structure facilitates activator binding and 
transcription apparatus recruitment.  However, in some cases, activators bind to 
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specific promoters in the distinct physical context provided by nucleosome 
(Chavez 1997, Cirillo 1999, Schild 1993). 
Chromatin modification 
Classes and functions.  Higher order of chromatin structures, usually 
mediated by modification of N-terminal tails of histones, are correlated with 
transcription regulation (Durrin et al, 1991).  Histones can be modified by 
acetylation, phosphorylation, methylation ubiquitination and sumoylation.  
Histone acetylation is the best understood histone modification.  Chromatin with 
histone hyperacetylation is more accessible to transcription apparatus and 
therefore is associated with active transcription. Histone acetylation activates 
transcription through several mechanisms: (1) providing greater access to DNA 
sequence for the transcription apparatus and its regulators by disrupting higher 
order chromatin structures, (2) decreasing their affinity for DNA or neighboring 
nucleosomes by disrupting nucleosome structure, (3) promoting or suppressing 
interactions with specific transcription factors.  Histone phosphorylation and 
ubiquitination are correlated with increased transcriptional activity.  Whether 
Histone methylation activates or represses transcription depends on the types of 
methylation of H3, H4 and H2. 
Acetylation and transcription.  Although RNA synthesis can be affected 
by histone acetylation was discovered early in 1964 by Allfrey et al, the link 
between transcription and acetylation wasn’t established until Brownell and 
Schreiber found that a histone acetyltransferase (HAT) and a histone de-
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acetyltransferase (HDAC) they identified are homologs to yeast transcription 
factors Gcn5 and Rpd3 respectively (Allfrety et al, 1963; Brownell et al, 1996; 
Schreiber et al 1996).  Since then, a large number of HATs have been 
discovered and are found to be previously identified transcriptional coactivators 
(Table 1.1.1).  HATs can be divided into two classes based on their cellular 
locations: type A HATs are localized in nuclei and acetylate nuclear factors; type 
B HATs are localized in cytoplasm and acetylate newly synthesized histones in 
the process of histone assembly.  In vivo, HATs function in association with 
multisubunit complexes.  Each HAT may show different substrate specificity in 
different complexes.  For example, Gcn5 is the catalytic component in SAGA, 
ADA and SLIK (SAGA like) /SALSA (SAGA altered) complexes (Grant et al 1997, 
Sterner et al 2002).  SAGA (Spt-Ada-Gcn5 Acetylatransferase complex) is a 1.8-
MDa complex, comprises of four classes of proteins: (1) Ada proteins (Ada1, 
Ada2, Ada3, Gcn5 and Ada5); (2) TBP-related Spt proteins (Spt3, Spt7, Spt8 and 
Spt20); (3) TBP-associated factors (TAF5, TAF6, TAF9, TAF10 and TAF12); and 
(4) Tra1.  SAGA complex has a variant, SALSA (or SLIK), which functions in 
retrograde response pathway with a truncated form of Spt7 and lacking Spt8 
(Grant 2002).  The structure of SAGA complex was revealed by Schultz lab using 
immuno-electron microscopy method (Wu et al, 2004).  They showed that SAGA 
is a modular complex with five distinct domains (Figure 1.1.2).  Domain II&IV 
contain TAFs that may provide histone folding functions.  Domain III is a central 
architectural domain with HAT activity.  Domain V may represent TBP interacting 
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surface.  Domain I contains a 400kDa protein, Tra1, representing the activator 
interacting surface. 
 
1.1.4 Tra1 in transcriptional regulation 
Tra1 functions 
Tra1 is the yeast homolog of human TRRAP 
(Transformation/Transcription domain-Associated Protein).  TRRAP was 
originally discovered by McMahon and Cole in 1998 (McMahon et al, 1998), who 
found TRRAP bound to c-Myc and E2F and mediated transformation.  Yeast 
homolog Tra1 is a 400kDa protein and belongs to the phosphatidylinositol 3-
kinase (PI3K)-related protein kinase (PIKK) protein family, which regulates 
signaling pathways by serine/threonine phosphorylation (Figure 1.1.3). Tra1 is an 
essential gene for yeast viability and a scaffold protein in SAGA, ADA and NuA4 
acetyltransferase complexes (Grant et al, 1998; Saleh et al, 1998).  Tra1 
regulates many cellular functions, such as cell cycle progression, cell dividing, 
DNA repair, etc.  Given its gigantic size and essential role in cell viability, it is 
challenging to study the structure and the functions of Tra1.   
Tra1 structure 
Although Tra1 retains the structure of the PI3K domain, it does not have 
the catalytic function, because it lacks several critical residues essential for 
protein phosphorylation (Knutson and Hahn, 2010). Mutiu and Brandl using 
targeted mutagenesis identified functional residues that are critical to cell 
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viability, temperature sensitive growth and growth on 6% ethanol (Mutiu et al 
2007).  Knutson and Hahn made 42 tra1 mutants with ~100 aa deletions and 
identified the regions that are critical for cell viability, association with SAGA and 
NuA4 complexes (∆24), HAT specificity and activity (∆32), activator interaction 
(e.g. ∆2, ∆5) (Knutson, 2011). 
 
1.1.5 Gal4-directed transcriptional regulation 
Gal4 Structure 
Gal4 is one of the best investigated activators of yeast transcription. Gal4 
is an 881aa protein member of the zn(II)2Cys6 (zinc cluster) family proteins 
(Figure 1.1.3).  It has a Zn-Cys DNA binding domain, a linker domain, a 
dimerization domain and two acidic activation domains (Lohr, 1995, FASEB).  
The consensus DNA binding site for Gal4 is a 17mer sequence 5’-CGG-N11-
CGG-3’.  Using X-ray crystallography, Marmorstein and Harrison showed that 
N’terminal fragment (DNA binding domain) binds to the consensus UAS as a 
dimer (Marmorstein, 1992).  Reece and Ptashne further identified that a 19aa 
region at the C-terminal to the Zn-Cys cluster directs the specificity of Gal4 
binding.  The gene structure of Gal4 is illustrated in Figure 1.1.3.   
Gal4 functions 
Gal4 regulates expression of most genes in galactose utilization pathway 
when glucose or other carbon sources are not available.  These genes function 
in transportation of galactose into the cell and its metabolism through the 
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glycolytic pathway.  There are two classes of GAL genes that are required for the 
growth of yeast on galactose:  structural genes (GAL1, GAL10, GAL2 and GAL7) 
and regulatory genes (GAL4, GAL80 and GAL3).  Transcription induction of the 
GAL structural genes by galactose is dependent on Gal4 binding to the UAS in 
their promoters.  The number of Gal4 binding sites and the space between the 
triplets in the consensus sequence determine their affinity for Gal4 activator and 
lead to differential activation (Lohr, 1995).  Besides GAL genes, some genes that 
are required for global adaptation to growth on galactose, such as MTH1, PCL10 
and FUR4, are also regulated by Gal4 (Ren, 2000).  
Gal4 regulation 
Gal4 activating transcription is the earliest and most well studied model 
system for investigating transcription regulation in yeast (Figure 1.1.4).  In the 
absence of galactose, Gal4 is inactivated by binding of Gal80 at its activation 
domain, rendering incapable to interact with transcriptional co-factors (Wu 1996; 
Carrozza, 2002).  In the presence of galactose, the interaction between Gal3 and 
Gal80 causes conformational change in the Gal80-Gal4 complex, exposes the 
Gal4 activation domain to the transcription co-factors and leads to the activation 
of transcription (Zenke, 1996; Leuther, 1992).  This is confirmed by in vivo 
protein-protein interaction assay, fluorescence resonance energy transfer 
(FRET), showing that Gal4 interacted with Gal80 in the presence of galactose 
(Bhaumik, 2004).  Peng and Hopper believed that Gal3 interacted with Gal80 and 
dissociated it from Gal4 by “shuttling” it to the cytoplasm (Peng and Hopper, 
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2000, 2002).  However, our work showed that Gal80 was still associated with 
Gal4 in nucleus after galactose induction. 
Gal4 targets 
Gal4 activates transcription by recruiting transcription co-activators and 
general transcription factors to the UAS through its activation domain.  The 
pivotal questions are how does it recruit other factors and what are the targets.  
There are many proteins that have been shown to interact with Gal4-activation 
domain:  TBP (Melcher, 1995; Wu, 1996), TFIIB (Wu, 1996), Gal11 (Jeong, 
2001), Srb10 (Ansari, 2002) and SWI/SNF (Yudkovsky, 1999) were identified 
interacting with Gal4 AD using in vitro binding assay with purified proteins; Srb4 
was identified using affinity chromatography, label transfer affinity-photo-cross-
linking and surface plasmon resonance (Koh, 1998); Sug1 (Gonzalez, 2002) and 
Sug2 (Chang et al, 2001) were identified to interact with Gal4 using in vitro 
binding assay and in vivo cytotrap assay; SAGA was identified as Gal4 AD target 
using label transfer affinity-photo-cross-linking assay (Brown, 2001) and FRET 
(Bhaumik, 2004).   
Gal4 alone is sufficient to recruit SAGA to the UAS, suggesting that it’s a 
direct target of Gal4 activation domain (Bhaumik et al 2001, Bryant et al 2003, 
Larschan et al 2001, 2005).  In addition, Bhaumik and Green showed that SAGA 
works as a scaffold for PIC assembly at the promoter instead of (or other than) 
HAT, because its catalytic subunit, Gcn5, is not required for SAGA recruitment 
and PIC formation (Bhaumik et al 2001).  Furthermore, they showed that one of 
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the 22 subunits of SAGA complex, Tra1, is the direct target of Gal4 activation 
domain, and the interaction happens on the promoter (Bhaumik et al 2004).   
In many of these target finding experiments, mutations in Gal4 activation 
domain were used to compromise its interaction with proposed targets, therefore 
confirm the specificity of the interaction.  However, we think it’s not sufficient to 
prove the direct interaction(s) in vivo.  What has been lacking is a reciprocal 
mutation in a target that prevents interaction with Gal4 and does not disrupt 
interactions between the Gal4 AD and any of its other putative targets. In the 
next chapter, we described Tra1 mutants that are selectively defective for 
interaction with Gal4, and use them to study how Gal4 stimulates transcription in 
vivo and the basis by which Tra1 is recognized by Gal4 and other activators.  
Figure 1.1.1 
UAS TATA INR 
DBD 
AD 
UAS TATA INR 
DBD 
AD 
TRA1 
TFIID TFIIA 
TFIIB 
RNA polymerase 
II 
TFIIF 
TFIIH TFIIE 
HAT(SAGA) 
16 
A 
B 
C 
UAS TATA INR 
DBD 
AD 
TRA1 
TFIID TFIIA 
TFIIB 
HAT(SAGA) 
Figure 1.1.1. Formation of the PIC on the promoter 
occurs in a series of ordered steps: (A) Activator binds 
to the promoter and recruits transcription co-activators. 
(B)TFIID recognizes of a promoter and forms nucleus of 
transcription initiation complex; TFIIB recognizes the 
TFIID-promoter complex and form DNA binding (DB) 
complex; (C) TFIIF/pol II complex is recruited to the 
promoter.  Recruitment of TFIIE and TFIIH completes the 
PIC formation.   
AD: activation domain; DBD: DNA binding domain; UAS: 
upstream activation sequence;  HAT: Histone 
acetyltransferase; SAGA: saga spt-ada-gcn5-
acetyltransferase. 
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Figure 1.1.2 
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Figure 1.1.2. SAGA is a modular complex with five 
distinct domains.  Domain II&IV contain TAFs that may 
provide histone folding functions.  Domain III is a central 
architectural domain with HAT activity.  Domain V may 
represent TBP interacting surface.  Domain I contains a 
400kDa protein, Tra1, representing the activator interacting 
surface. 
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Figure 1.1.3. (A) Structure of Tra1.  Tra1 consists of a 
HEAT  domain (Huntingtin, elongation factor 3, PR65/A, 
and TOR), a FAT domain (FRAP, ATM, and TRRAP), a FRB 
domain (FKBP12 rapamycin binding), a PI3K domain and a 
FATC domain (FAT C-terminal).  (B) Gal4 has a DNA 
binding domain, a linker domain, a dimerization domain 
and two acidic activation domains.   
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Figure 1.1.4.  In the absence of galactose, Gal4 is 
inactivated by binding of Gal80 at its activation domain, 
rendering incapable to interact with transcriptional co-
factors.  In the presence of galactose, the interaction 
between Gal3 and Gal80 causes conformational change in 
the Gal80-Gal4 complex, exposes the Gal4 activation 
domain to the transcription co-factors and leads to the 
activation of transcription. 
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Table 1.1.1 Histone acetylation enzymes and complexes 
 
Acetylation  
Hat1 subunit of the Hat1p-Hat2p HAT complex, acetylates nuclear and 
cytoplasmic histone H4 
Gcn5 Subunit of the ADA and SAGA HAT complex, modifies histone 
H2B and H3 
Hpa2 Acetylates histones H3 and H4, autoacetylation 
Esa1 MYST family, essential for viability, acetylates histone H4 
Sas3 MYST family, subunit of NuA3 complex, acetylates histone H3, 
transcriptional cilencing 
Elp3 Subunit of elongator complex, acetylates histone H3 and H4 
TAFII145 Subunit of TAFIID 
  
SAGA Tra1, Ada2, Gcn5, Spt3, Spt7, Spt8, 
Spt20, Taf5, Taf6, Taf9, Taf10, Taf12, 
Chd1Sgf11, Sgf29, Sgf73, Ubp8, Ngg1, 
Hfi1, Sus1 
Interacts with acidic 
activation domains and TBP. 
HAT activity stimulates 
transcription. Acetylates 
histone H3 and H2B 
SLIK Tra1, Ada2, Gcn5, Spt3, Spt7(truncated 
form), Spt20, Taf5, Taf6, Taf9, Taf10, 
Taf12, Chd1Sgf11, Sgf29, Sgf73, Ubp8, 
Ngg1, Hfi1, Sus1 
HAT activity stimulates 
transcription. Acetylates 
histone H3 and H2B 
NuA4 Tra1, Eaf1, Eaf3, Eaf5, Eaf6, Eaf7, Ynf2, 
Swc4, Esa1, Epl1, Yaf9 
Interacts with acidic 
activation domains. HAT 
activity stimulates 
transcription in vitro. 
Acetylates histone H4 and 
H2A 
NuA3 Eaf6, Taf14, Nto1, Sas3, Yng1 Acetylates hitstone H3 
ADA Ahc1, Ada2, Ahc2, Ngg1, Sgf29, Gcn5 Acetylates histone H3 and 
H2B 
Elong
ator 
Elp2, Elp3, Elp4, Iki1,Iki3 Transcription elongation. 
Acetylates histones H2A, 
H2B, H3 and H4 
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CHAPTER II 
 
Analysis of Gal4-directed transcription activation 
using Tra1 mutants selectively defective 
for interaction with Gal4 
  26 
 
Abstract  
Promoter-specific transcriptional activators (activators) stimulate 
transcription through direct interactions with one or more components of the 
transcription machinery, termed the “target”. The identification of direct in vivo 
targets of activators has been a major challenge. Previous studies have provided 
evidence that the Tra1 subunit of the yeast SAGA (Spt-Ada-Gcn5-
acetyltransferase) complex is the target of the yeast activator Gal4. However, 
several other general transcription factors, in particular the mediator complex, 
have also been implicated as Gal4 targets.  Here, we performed a large-scale 
genetic screen to derive and characterize tra1 alleles that are selectively 
defective for interaction with Gal4 in vivo (Gal4 interaction defective (GID) 
mutants). In contrast to wild-type Tra1, Tra1 GID mutants are not recruited by 
Gal4 to the promoter and cannot support Gal4-directed transcription, 
demonstrating the essentiality of the Gal4–Tra1 interaction. In yeast strains 
expressing a Tra1 GID mutant, binding of Gal4 to the promoter is unexpectedly 
also diminished, indicating that Gal4 and Tra1 bind cooperatively. Consistent with 
cooperative binding, we demonstrate that the Gal4–Tra1 interaction occurs 
predominantly on the promoter and not off DNA. Finally, we show that although 
Tra1 is targeted by other activators, these interactions are unaffected by GID 
mutations, revealing an unanticipated specificity of the Gal4–Tra1 interaction. 
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Introduction 
Transcription is a highly regulated process.  The basal transcription 
requires minimal protein apparatus for accurate transcription initialtion: General 
transcription factors (GTFs) and the subunits of RNA polymerase II. Transcription 
initiation by RNA polymerase II involves the assembly of general transcription 
factors on the core promoter to form a preinitiation complex (PIC).  In the cells, 
genes packaged into chromatin are in general repressed.  Therefore, assembly 
of the GTFs at the promoter must be triggered by activator proteins.  Promoter-
specific activator proteins (activators) can recruit GTFs to a sequence specific 
promoter to accelerate PIC formation and induce the expression of genes 
(Roeder, 1996; Orphanides, 1996; Ptashne, 1997; Lee, 2000).  Activators can 
stimulate transcription at various steps: (1) remove repressors from promoter; (2) 
recruit GTFs and pol II to the promoter; (3) induce conformational change of PIC; 
(4) induce covalent modification of proteins in the PIC; and (5) stimulate promoter 
clearance and elongation.  Activators can recruit factors that remodel 
nucleosomes and make promoter sequences more accessible for GTFs and pol 
II.  H3 and H4 histones are reversibly acetylated.  The acetylation of the lysine 
residues reduces the interaction between histone and DNA by neutralizing their 
positive charge.  Activators that recruit histone acetyltransferase complex 
stimulate transcription by removing the histones athe the promoter.  Activators 
are modular proteins that contain a DNA-binding domain (DBD) and an activation 
domain (AD). Activator-mediated stimulation of PIC assembly is believed to result 
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from a direct interaction between the AD and one or more components of the 
transcription machinery, termed the “target”. The unambiguous identification of 
the direct in vivo targets of activators has been a major challenge in the field. 
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Results 
Isolation of tra1 Mutants that Cannot Support Growth on Galactose.  
The strategy we used to derive Tra1 mutants that fail to interact with the 
Gal4 AD is summarized in Figure. 1.2.1.A and described below. We generated a 
library of random tra1 mutants by in vitro hydroxylamine mutagenesis of a low-
copy plasmid expressing TRA1. The library was transformed into a haploid yeast 
tra1-∆ strain that was complemented by wild-type (WT) TRA1 expressed on a 
low-copy URA3-containing plasmid. Following eviction of the WT TRA1 plasmid 
on media containing 5-fluoroorotic acid (5-FOA), strains harboring the tra1 
mutants were analyzed for growth on media containing glucose (YPD), but not 
galactose (YPG). This approach yielded 13 tra1 mutants that were unable to 
support growth on YPG (Figure. 1.2.1.C). 
Sequence analysis revealed that the 13 tra1 mutants represented eight 
distinct alleles (Figure. 1.2.1.B). Mutants 2-7 were found to contain the same 
mutations and therefore, of these mutants, only tra1-mut2 was further analyzed. 
Immunoblot analysis showed that all of the Tra1 mutants were expressed at 
levels comparable to that of WT Tra1 (Figure 1.2.2.A). 
To confirm that the tra1 mutants selectively abolished GAL gene 
expression, we monitored expression of two GAL genes, GAL1 and GAL3, by 
quantitative RT-PCR (qRT-PCR). In strains harboring the eight tra1 mutants, 
transcription of GAL1 and GAL3 in galactose-containing media was severely 
compromised relative to that observed in a WT TRA1 strain (Figure. 1.2.2.B). By 
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contrast, expression of RPS5 and RPS0B, which are SAGA-independent genes, 
were unaffected by the tra1 mutants (Figure. 1.2.2.C). 
 
Development of a Bimolecular Fluorescence Complementation Assay for 
Detecting Interactions Between Activators and Tra1 in vivo.  
To detect direct interactions between the mutant Tra1 proteins and Gal4 in 
vivo, we developed a bimolecular fluorescence complementation (BiFC) assay, 
which has been used for the in vivo detection of a wide variety of protein–protein 
interactions (Akman, 2009; Sung, 2007). The BiFC assay is based on the 
formation of a fluorescent complex comprising two fragments of yellow 
fluorescent protein (YFP), which are brought together by association of two 
interacting proteins fused to the fragments (reviewed in Kerppola 2008). 
To verify the feasibility of this approach, we first performed a series of 
control experiments that monitored the interaction between Tra1 and two SAGA-
dependent activators, Gal4 and Gcn4. The experimental strategy for detecting 
activator–Tra1 interactions using the BiFC assay is shown in Figure. 1.2.3.A. We 
derived a pair of haploid yeast strains, one in which the endogenous Tra1 protein 
was tagged at the C-terminus with the N-terminal fragment of a YFP variant 
known as Venus (Nagai, 2002) (Tra1-VN), and a second strain of opposite 
mating type in which the endogenous activator was tagged at its C-terminus with 
the C-terminal Venus fragment (Gal4-VC or Gcn4-VC). The two haploid strains 
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were then mated, and the resulting diploid cells were analyzed by fluorescence 
microscopy for a nuclear BiFC signal. 
As described above, because of Gal80-mediated inhibition, the Gal4–Tra1 
interaction is expected to occur in the presence but not the absence of galactose. 
Figure. 1.2.3.B (top panel) shows that a BiFC signal was detected in cells 
expressing Tra1-VN and Gal4-VC and grown in YPG but not YPD. Identical 
results were obtained when the Venus fragment was fused to Tra1 at its N-
terminus (VN-Tra1) (Figure. 1.2.3.B, bottom panel). Thus the BiFC assay 
detected the Gal4−Tra1 interaction, which, as expected, was galactose 
dependent. 
A Gcn4–Tra1 interaction is expected to occur only under conditions of 
amino acid starvation. Figure. 1.2.3.C shows that a nuclear BiFC signal was not 
detected in cells expressing Tra1-VN and Gcn4-VC grown in nutrient-rich media 
(YPD), but was readily detected in amino acid-starved cells grown on histidine 
(His)-lacking medium in the presence of the competitive inhibitor 3-aminotriazole 
(3-AT). Collectively, the results of Figure. 1.2.3 demonstrate that the BiFC assay 
can be used to detect interactions between activators and Tra1. 
 
Identification of Tra1 Mutants that are Unable to Interact with Gal4 
We used the BiFC assay to analyze the interaction between Gal4 and the 
Tra1 mutants. In these and subsequent BiFC experiments described below, the 
endogenous activator was tagged at the C-terminus with VC in a haploid tra1-∆ 
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strain that was complemented by WT TRA1 expressed on a URA3-containing 
plasmid. The strain was then transformed with a low-copy plasmid expressing a 
Tra1 mutant protein fused to VN at either the C-terminus (Tra1-mut1, -mut2, -
mut8, -mut9, -mut12 and -mut13) or N-terminus (Tra1-mut10 and -mut11), and 
the BiFC signal was monitored following eviction of the WT TRA1 plasmid. As 
expected, in cells expressing WT Tra1-VN, a nuclear BiFC signal could be 
detected upon growth on galactose (Figure. 1.2.4). By contrast, a BiFC signal 
was not detected in cells expressing any of the Tra1 mutants. 
We have previously proposed that Tra1 must be incorporated into an 
intact SAGA complex for interaction with Gal4 in vivo (Bhaumik et al 2004). 
Therefore, one explanation for the inability of the Tra1 mutants to interact with 
Gal4 is a failure to be incorporated into SAGA. To address this issue, we 
analyzed the stable association between Tra1 mutants and the SAGA subunit 
Spt20 in a co-immunoprecipitation assay. Figure. 1.2.5.A shows that Tra1-mut1 
and Tra1-mut8 co-immunoprecipitated with Spt20 at levels comparable to that of 
WT Tra1. By contrast, the other mutants were completely (Tra1-mut2, -mut9, -
mut10, -mut12 and -mut13) or partially (Tra1-mut11) defective for interaction with 
Spt20. Tra1 is also a subunit of another HAT complex known as NuA4 (Allard et 
al 1999). Figure. 1.2.5.B shows that all Tra1 mutants co-immunoprecipitated with 
the NuA4 subunit Eaf1, indicating that they were all efficiently incorporated into 
the NuA4 complex. Collectively, these results indicate that Tra1-mut1 and Tra1-
mut8 are incorporated into the SAGA complex but are unable to interact with 
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Gal4 and thus can be classified as Gal4 interaction defective (GID) mutants. 
Tra1-mut8 is of particular importance because it contains only a single amino 
acid substitution at position 400 (H400Y) (see Figure. 1.2.1.B). The inability of 
Tra1-mut1 and Tra1-mut8 to interact with Gal4 and support transcription of GAL 
genes conclusively establishes that the Gal4–Tra1 interaction is essential for 
Gal4-directed transcription activation. 
 
Gal4 and Tra1 Bind Cooperatively to the GAL1 Promoter 
The interaction between Gal4 and Tra1 is expected to result in recruitment 
of the SAGA complex to the promoters of GAL genes. Therefore, in a yeast strain 
expressing a Tra1 GID mutant, the SAGA complex should not be recruited to 
GAL genes. To confirm this prediction, we performed a series of chromatin 
immunoprecipitation (ChIP) assays. As expected, in galactose association of 
Tra1-mut1 and Tra1-mut8 with the GAL1 promoter was substantially reduced 
relative to WT Tra1 (Figure. 1.2.6.A). Likewise, association of Spt20 with the 
GAL1 promoter was comparably reduced in the two Tra1 GID mutant strains. By 
contrast, recruitment of Tra1-mut1 and Tra1-mut8 to the promoter of RPS0B, a 
NuA4-dependent gene, was comparable to that of WT Tra1. 
Figure. 1.2.6.A also shows that in raffinose Gal4 binding was roughly 
equivalent in the WT Tra1 and Tra1 GID mutant strains. Unexpectedly, in 
galactose binding of Gal4 to the GAL1 promoter was substantially reduced in the 
Tra1 GID mutant strains. We interpret this result to indicate that the Gal4–Tra1 
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interaction enhances the ability of Gal4 to bind the promoter. Binding of Gal4 to 
the GAL1 promoter was also reduced in an spt20-∆ strain (Figure. 1.2.6.B), 
which does not support the Gal4–Tra1 interaction (Bhaumik et al 2002). 
Collectively, the results of Figures. 1.2.6.A and B indicate that as a result of the 
Gal4–Tra1 interaction, Gal4 and Tra1/SAGA bind cooperatively to the promoter. 
 
The Gal4–Tra1 Interaction Occurs Predominantly on the Promoter and Not 
Off DNA.  
An important, unresolved question is whether in vivo the interaction 
between an activator and its target occurs predominantly on the promoter or 
whether the activator–target interaction is sufficiently stable that it occurs off 
DNA. To address this issue, we used the BiFC assay to monitor the interaction 
between Tra1 and a LexA-Gal4 AD fusion-protein that can bind to DNA only in 
yeast strains engineered to contain LexA-binding sites. A summary of the 
experimental design is shown in Figure. 1.2.7.A and discussed below. We first 
constructed a haploid tra1-∆ strain harboring plasmids expressing Tra1-VN and a 
LexA DBD-Gal4 AD fusion-protein tagged with the C-terminal Venus fragment 
[LexA(DBD)-Gal4(AD)-VC]. This strain was transformed with a series of 
constructs to derive three strains, the first of which (strain 1) expressed a high-
copy plasmid containing four LexA-binding sites located upstream of a GAL1-
lacZ reporter gene (West et al 1984). Strain 2 was identical to strain 1 except that 
the construct lacked upstream LexA-binding sites (West et al 1984). In strain 3 
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the GAL1 core promoter sequence, which is the site at which SAGA and other 
PIC components are recruited, was deleted from the GAL1-lacZ reporter gene. 
Immunoblot analysis confirmed that the LexA(DBD)-Gal4(AD)-VC fusion-protein 
was expressed equivalently in the three strains (Figure. 1.2.7.B). 
We analyzed the interaction between the Gal4 AD and Tra1 in these three 
strains using the BiFC assay. Figure. 1.2.8.A shows that a nuclear BiFC signal 
was detected in strain 1 but not in strain 2, indicating a requirement for LexA-
binding sites. As expected, in strain 1, the nuclear BiFC signal was observed only 
in galactose. The nuclear BiFC signal was also absent from strain 3, which 
lacked the GAL1 core promoter. Collectively, these results indicate that the Gal4 
AD–Tra1 interaction occurs predominantly on DNA, and is dependent upon both 
activator-binding sites and the core promoter.  Previous report shows that Gal4 
binding to the promoter is independent of Gal4-Tra1 interaction by chromatin 
immunoprecipitation that facilitated by formaldehyde crosslinking (Bauhmik, 
2002).  By using BiFC assay, we could monitor the real-time interaction between 
activator and Tra1 that not affected by crosslinking reagent. 
 As a control, we performed an analogous experiment to monitor the 
interaction between Gal4 and its negative regulator Gal80. Figure. 1.2.8.B shows 
that a nuclear BiFC signal was detected in all three yeast strains indicating, as 
expected, that the Gal4–Gal80 interaction is not dependent upon either activator 
binding sites or the core promoter. Notably, unlike the Gal4–Tra1 interaction, the 
Gal4–Gal80 interaction occurred in both raffinose and galactose, which is in 
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agreement with previous biochemical experiments showing that in galactose 
Gal80 remains physically associated with Gal4 at a second site (Sil et al 1999). 
 
 
The Gal4-Interaction Site on Tra1 is Highly Selective 
We next performed experiments to determine whether the Tra1 GID 
mutants were selectively defective for interaction with the Gal4 AD or were 
unable to interact with other activators that also targeted Tra1. Figure. 1.2.9.A 
shows that both Tra1 GID mutant strains grew on His-lacking medium containing 
3-AT, indicating that the mutants could support Gcn4-directed transcription. 
Furthermore, a nuclear BiFC signal could be detected in strains expressing 
Gcn4-VC and either WT Tra1 or a Tra1 GID mutant (Figure. 1.2.9.B). Thus, 
unlike Gal4, Gcn4 functionally interacts with Tra1 GID mutants. 
 To further investigate the selectivity of the Gal4 interaction site on Tra1, 
we sought to identify other activators that interact with Tra1 in the SAGA complex 
and determine their sensitivity to the Tra1 GID mutations. Toward this end, we 
first identified Tra1-dependent genes by comparing the mRNA population of a 
WT TRA1 strain to that of a strain bearing a temperature-sensitive tra1 allele 
(tra1-2ts; ref. Kulesza et al 2002) under non-permissive conditions. Following 
inactivation of TRA1, ~3% of yeast genes were down-regulated greater than two-
fold (Table 1.2.1), consistent with a previous study that analyzed other tra1 
alleles (Mutiu et al 2007). 
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To identify a set of Tra1-dependent genes that were also SAGA-
dependent, we analyzed the 20 genes most affected by TRA1 inactivation (see 
Table 1.2.2) for dependence on Spt20. We first mined a published expression 
profiling study for genes whose transcription is compromised in an spt20-∆ strain 
(Lee et al 2000) and then confirmed these in silico results by qRT-PCR. This 
combined analysis identified 11 genes whose transcription was compromised by 
inactivation of Tra1 or loss of Spt20 (Figure 1.2.10.A). In addition, ChIP analysis 
showed, as expected, that Tra1 was bound to the promoters of all 11 genes 
(Figure. 1.2.10.B). Significantly, the two Tra1 GID mutants did not significantly 
affect transcription of any of these 11 Tra1- and SAGA-dependent genes (Figure 
1.2.10.A), suggesting that Tra1 GID mutants might be specific to Gal4 activation. 
Next, we tested the ability of the activators that mediate expression of the 
11 Tra1- and SAGA-dependent genes to interact with WT Tra1 and the Tra1 GID 
mutants. To identify activators involved in regulating expression of the Tra1- and 
SAGA-dependent genes, we searched published genome-wide ChIP-microarray 
(ChIP-chip) studies (Harbison, 2004; Iyer, 2001; Lee, 2002; Lieb, 2001; Ren, 
2000). Using this approach, predicted activators could be identified for 10 of the 
11 Tra1- and SAGA-dependent genes analyzed above (Table 1.2.2). 
We selected five activators for further analysis: Cbf1, Fkh2, Mcm1, Reb1, 
and Zap1. Figure 1.2.11 shows a nuclear BiFC signal was detected in yeast 
strains expressing WT Tra1-VN and either Cbf1-VC, Fkh2-VC, Mcm1-VC, Reb1-
VC or Zap1-VC. Thus, as predicted, all five of these activators directly interact 
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with Tra1. Notably, a nuclear BiFC signal was also observed with all five 
activators in strains expressing either Tra1 GID mutant. Thus, consistent with the 
transcription results of Figure. 1.2.10.A, these activators directly interact with 
Tra1, but this interaction is insensitive to the GID mutations. 
Finally, in an independent approach, we attempted to identify genes 
whose transcription was affected by the Tra1 GID mutants by comparing 
genome-wide expression profiles of yeast strains harboring either WT TRA1, 
tra1-mut1 or tra1-mut8 grown in YPD. Remarkably, we found only two genes 
(GSC2 and HSP30) whose expression was affected more than 2-fold by the tra1-
mut1 mutation and no genes that were affected more than 2-fold by the tra1-
mut8 mutation (Figure 1.2.12.A and Tables 1.2.3 and 1.2.4). Moreover, even for 
GSC2 and HSP30, qRT-PCR did not confirm the difference in expression levels 
observed by microarray analysis and instead revealed that expression of these 
two genes was comparable in tra1-mut1, tra1-mut8, and the WT TRA1 strains 
(Figure 1.2.12.B). Collectively, these results indicate that remarkably few, and 
possibly no other, yeast activators target the same Tra1 region at which Gal4 
interacts. 
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Material and Methods 
Plasmid and strain construction 
Plasmids pRS414-pDED1-myc-TRA1 and pRS416-pDED1-myc-TRA1 
were constructed by cloning the myc-TRA1 fragment from myc-TRA1-YCplac11 
(Saleh et al 1998) into pRS414 (CEN TRP1) or pRS416 (CEN URA3), 
respectively, using restriction enzyme Not I and Sal I. 
Strain LLY154 is a haploid tra1-∆ strain derived from MDC1 (Kulesza et al 
2002) in which the wild-type TRA1 plasmid was replaced with pRS416-pDED1-
myc-TRA1. For the qRT-PCR experiments shown in Figure 1.2.2, RNA was 
prepared from LLY154 transformed with a pRS414-based wild-type or mutant 
TRA1 plasmid following eviction of pRS416-pDED1-myc-TRA1 on 5-FOA. For 
the experiment shown in Figure 1.2.10, gene expression was analyzed in 
LLY154 harboring plasmids expressing TRA1, tra1-mut1 or tra1-mut8, in a 
haploid tra1-2ts (MDC3) or isogenic wild-type strain (MDC1; (Kulesza et al 2002), 
or in a haploid spt20-∆ strain (YDA352) or isogenic wild-type strain (FY23; 
(Winston et al 1995).  
To generate Tra1-VN- and VN-Tra1-tagged strains for the BiFC assay in 
Figure 1.2.3, the N-terminal fragment of Venus was PCR amplified from plasmid 
pFA6a-VN-His3MX6 and pFA6a-KanMX6-PCET1-VN, respectively (Sung et al 
2007), using primers (listed in Table 1.2.6) and transformed into haploid MATa 
strain BY4741 (Giaever et al 2002). To generate Gal4-VC and Gcn4-VC-tagged 
strains, the C-terminal fragment of Venus was PCR amplified from plasmid 
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pFA6a-VC-His3MX6 (Sung et al 2007) and transformed into haploid MATα strain 
BY4742 (Giaever et al 2002). Pair-wise haploid strain combinations were mated, 
and the BiFC signal in the resulting diploid cells was examined. 
For monitoring interactions between activators and Tra1 mutants, 
activators were C-terminally tagged at their endogenous locus, as described 
above, in strain LLY197, a haploid tra1-∆ strain harboring pRS416-pDED1-myc-
TRA1. The strains were then transformed with a plasmid expressing wild-type or 
mutant Tra1-VN (or VN-Tra1) [constructed by PCR amplifying the N-terminal 
fragment of Venus from plasmid pFA6a-VN-KanMX6 (Sung et al 2007) and 
inserting it into pRS414-based wild-type and mutant Tra1 plasmids], and the 
BiFC signal was monitored following eviction pRS416-pDED1-myc-TRA1 on 5-
FOA.  
To construct LexA(DBD)-Gal4(AD)-VC, the C-terminal Venus PCR 
fragment from pFA6a-VC-TRP1 (Sung et al 2007) was cloned into plasmid 
pSH17-4 (Wu et al 2000), which expresses a LexA(DBD)-Gal4(AD) fusion 
protein. The plasmid expressing LexA(DBD)-Gal4(AD)-VC was co-transformed 
into strain LLY210 (a haploid tra1-∆ strain harboring a plasmid expressing Tra1-
VN) together with pSH18-34 (harboring 4 LexA operators upstream of the GAL1-
lacZ reporter gene; (West et al 1984), a derivative of pSH18-34 in which the 
GAL1 promoter had been deleted; pSH18-34∆2) or LR1∆1 (harboring a GAL1-
lacZ reporter gene but lacking the LexA operators; (West et al 1984). For Figure 
1.2.8, Gal80 was C-terminally tagged at its endogenous locus by PCR amplifying 
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the N-terminal Venus fragment from pFA6a-VN-TRP1 (Sung et al 2007) and 
transforming it into W303, generating LLY326, which was then co-transformed 
with plasmids LexA(DBD)-Gal4(AD)-VC and pSH18-34, LR1∆1 or pSH18-34∆2. 
Strains were grown in galactose or raffinose, and cells were monitored for a BiFC 
signal. 
For the immunoblot experiment of Figure 1.2.2, whole cell extracts were 
prepared from strain LLY154 transformed with a pRS414-based WT or mutant 
Tra1 plasmid following eviction of pRS416-pDED1-myc-TRA1 on 5-FOA. For the 
co-immunoprecipitation experiments of Figure 1.2.5, Spt20 or Eaf1 was C-
terminally tagged at its endogenous locus with an HA epitope by PCR amplifying 
the HA tag from pFA6a-3HA-KanMX6 (Longtine et al 1998) and transforming it 
into strain LLY154. The strains were then transformed with pRS414-based WT or 
mutant Tra1 plasmids, and extracts were prepared following eviction of pRS416-
pDED1-myc-TRA1. 
ChIP was performed using strain LLY154 transformed with pRS414-based 
WT or mutant Tra1 plasmid or FY23 and YDA352 (Figure 1.2.6). 
 
TRA1 Mutagenesis Screen 
Plasmid pRS414-pDED1-myc-TRA1 was mutagenized by treatment with 
hydroxylamine solution [1M hydroxylamine (Sigma), 50 mM sodium 
pyrophosphate (pH 7.0), 100 mM NaCl, and 2 mM EDTA] at 75˚C for 30 mins 
(Guthrie et al 2004). The mutagenized library was amplified in bacteria and then 
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transformed into a haploid tra1-∆ strain LLY154 (see Table 1.2.5). Cells were 
plated on –Trp 5-FOA media, and ~1200 5-FOA-resistant colonies were patched 
and replica plated onto YPD and YPG media containing 20 µg/ml antimycin A 
(Sigma). Colonies able to grow on YPD but not YPG were selected, and the 
plasmid was isolated and sequenced. Strains carrying tra1-mut1 and tra1-mut8 
were also analyzed for growth on –His media containing 50 mM 3-AT. 
 
Quantitative RT-PCR 
Total RNA was extracted (Schmitt et al 1990), and reverse transcription 
was performed using SuperScript II Reverse Transcriptase (Invitrogen) followed 
by qPCR using Fast SYBR Green Master Mix (Applied Biosystems) using the 
primers listed in Table S6. For the experiments shown in Fig. 1B and S1D, cells 
were grown in 2% raffinose followed by 2% galactose for 5 mins.  
 
Bimolecular Fluorescence Complementation Assay 
The BiFC signal in cells was examined by fluorescence microscopy using 
a Zeiss AXIO Imager Z2 microscope. A total of 100 cells from at least 7 different 
fields were counted; representative examples are shown. 
 
Immunoblotting and Co-immunoprecipitation Assays 
For Figure 1.2.2, whole cell extracts were prepared as previously described 
(Brown et al 2001) and blots were probed with an anti-myc (Santa Cruz) or anti-
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actin (Abcam) antibody. For Figure 1.2.7, extracts were prepared from strains 
grown in galactose or raffinose medium, and blots were probed with an anti-LexA 
(Santa Cruz) or anti-actin (Abcam) antibody. For the co-immunoprecipitation 
experiments of Figure 1.2.5, Spt20-HA or Eaf1-HA was immunoprecipitated with 
an anti-HA antibody, and blots were probed with an anti-HA (Abcam) or anti-myc 
(Santa Cruz) antibody. 
 
Chromatin Immunoprecipitation 
ChIP was performed as described previously (Harbison et al 2004) using 
an anti-myc (Abcam), anti-HA (Abcam) or anti-Gal4 (Abcam) antibody. Following 
reversal of the crosslinks, the DNA was PCR-amplified using gene-specific 
primers (listed in Table 1.2.6). 
 
Microarray Analyses 
Strains MDC1 and MDC3 were grown at 30°C and shifted to 37°C for 60, 
90 and 120 mins. Haploid TRA1, tra1-mut1 and tra1-mut8 strains were generated 
as described in Supplemental Methods. RNA was extracted according to 
standard protocols (Schmitt et al 1990) and hybridized to an Affymetrix YG-S98 
array. The tra1-mut1/TRA1 and tra1-mut8/TRA1 experiments were done in 
duplicate. Statistical analyses were performed using R (Ihaka et al 1996). RMA 
method (Irizarry et al 2003) in Affy package from Bioconductor (Gentleman et al 
2004) was used to summarize the probe level data and normalize the dataset to 
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remove across array variation. Limma package (Smyth 2004) with randomized 
block design was used to determine whether a gene’s expression level differs 
between mutant and WT regardless of time point. Genes with adjusted p-value 
using B-H method (Benjamini 1995) < 0.05 was considered significant. The 
microarray data from this publication have been deposited in NCBI’s Gene 
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession 
number GSE31391. 
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Discussion 
 
The results presented in this manuscript definitively establish Tra1 as an 
essential in vivo target of Gal4 by identifying the site on Tra1 at which Gal4 
interacts and demonstrating the necessity of this interaction for Gal4-directed 
transcription. For Tra1 to interact with Gal4 it first must be incorporated into an 
intact SAGA complex. The amino acids in Tra1 that we find compromise 
assembly into the SAGA complex are consistent with the results of a recent study 
analyzing Tra1 functional domains (Knutson et al 2011). Our results indicate that 
Tra1 does not have an intrinsic ability to interact with the Gal4 AD but rather 
requires proper presentation within the SAGA complex. It seems likely that this 
finding is relevant to the selective interaction of Gal4 with SAGA and not the 
NuA4 complex, which also contains Tra1. 
Several experimental observations have led to the suggestion that an 
activator will have multiple, functionally redundant targets. For example, in vitro 
protein–protein interaction experiments have shown that a single activator such 
as Gal4 (reeves, 2005; Wu, 1996; Melcher, 1995; Neely, 2002; Bryant, 2003; 
Jeong, 2001; Koh, 1998; Park, 2000) or Gcn4 (Drysdale, 1998; Utley, 1998) can 
interact with multiple components of the transcription machinery. Likewise, in 
artificial recruitment experiments, a wide variety of transcription components can 
stimulate transcription and thus could potentially function as targets (Ptashne, 
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1997). However, in contrast to this view, we demonstrate that interaction of Gal4 
with a single site on Tra1 is required for Gal4-directed transcription. 
 The fact that many yeast activators contain acidic ADs, with apparently 
similar sequence features, has suggested that activators have common targets 
and recognition sites. Consistent with this idea, in vitro protein crosslinking 
experiments have shown that both the Gal4 and Gcn4 ADs interact with three 
common proteins; Tra1, Gal11 and Taf12 (Fishburn, 2005; Reeves, 2005). 
Surprisingly, however, we find that the Gal4-interaction region on Tra1 is 
remarkably specific and that the Gal4 and Gcn4 ADs recognize Tra1 
differentially. Our collective results suggest that at most very few, and likely no 
other, yeast activators functionally interact with the same region of Tra1 that is 
recognized by the Gal4 AD. 
 In this study, we have performed a series of BiFC experiments whose 
results show that the interaction between the Gal4 AD and Tra1 occurs 
predominantly on the promoter and not off DNA. These new results explain our 
previous finding that a Gal4 mutant lacking its DBD failed to interact with Tra1 in 
vivo (Bhaumik, 2004). Our results help explain how cellular activators avoid a 
transcription inhibitory process referred to as “squelching”, which occurs following 
over-expression of a strong AD, such as the herpes simplex virus VP16 AD (Gill, 
1988; Triezenberg, 1988). Squelching results from the sequestration of the target 
by the activator off the promoter; the target is thus unavailable for promoter-
bound activators resulting in transcriptional inhibition. By interacting with Tra1 
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predominantly on the promoter and not off DNA, Gal4 avoids squelching. 
Squelching is dependent upon both the strength and concentration of the over-
expressed AD (Gill, 1988; Triezenberg, 1988). Based upon these considerations, 
we speculate that cellular activator-target interactions are in general weak, thus 
ensuring that they occur only on the promoter where they are stabilized by the 
many other protein–protein and protein–DNA interactions in the PIC. 
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Figure 1.2.1 
C 
Figure 1.2.1. Isolation of tra1 mutants that cannot 
support growth on galactose. (A) Schematic for 
mutagenesis of TRA1 and selection of mutants that fail to 
grow on galactose. (B) Summary of the mutated residues 
in each of the tra1 mutants. (C) Growth of tra1 mutants 
1-13 on YPD and YPG media supplemented with 
antimycin. Growth of WT TRA1 and gal4-∆ strains are 
shown as controls. Cells were spotted as 10-fold serial 
dilutions.  
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Figure 1.2.2 
Figure 1.2.2. Analysis of tra1 mutants that cannot 
support growth on galactose. (A) Immunoblot analysis 
showing levels of WT and mutant Tra1 proteins. Actin 
(Act1) was monitored as a loading control. (B) qRT-PCR 
analysis monitoring expression of GAL1 and GAL3 in 
strains expressing WT TRA1 or tra1 mutant grown in 
raffinose or galactose. (C) qRT-PCR analysis monitoring 
expression of RPS5 and RPS0B in strains expressing WT 
TRA1 or each of the tra1 mutants grown in raffinose or 
galactose. Expression of each gene was normalized to 
that observed in the WT TRA1 strain grown in raffinose, 
which was set to 1. The fold induction in galactose in the 
WT TRA1 strain is indicated. Error bars indicate standard 
deviation. 
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Figure 1.2.3 
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A B 
C 
Figure 1.2.3. Development of a bimolecular 
fluorescence complementation assay for detecting 
interactions between activators and Tra1 in vivo. (A) 
Schematic diagram depicting the BiFC assay. Tra1 is 
tagged at the C-terminus with the N-terminal Venus 
fragment (VN), and the activator (Act) is tagged at the C-
terminus with the C-terminal Venus fragment (VC). (B) 
BiFC assay monitoring interaction between Tra1 and Gal4 
in vivo, as evidenced by intense YFP signal (arrowheads) 
in YPG. The Tra1–Gal4 interaction occurs in the nucleus, 
as evidenced by co-localization (arrowheads) with the 
DNA stain 4',6-diamidino-2-phenylindole (DAPI). Tra1 was 
tagged at either the C-terminus (top panels) or N-terminus 
(bottom panels). (C) BiFC assay monitoring interaction 
between Tra1 and Gcn4 in vivo, as evidenced by intense 
YFP signal in response to amino acid starvation (–His + 3-
AT media). 
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Figure 1.2.4 
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Figure 1.2.4. Identification of Tra1 mutants that are 
unable to interact with Gal4.  BiFC assay monitoring the 
interaction between Gal4 and the mutant Tra1 proteins.  
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Figure 1.2.5 
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Figure 1.2.5. Identification of Tra1 mutants that are 
unable to interact with HATs complexes. (A) Co-
immunoprecipitation assay. Spt20-HA was 
immunoprecipitated with an anti-HA antibody, and the 
immunoprecipitate analyzed for the presence of Tra1. The 
levels of Spt20 and Tra1 in the input extract are shown.  
(B) The Tra1 mutants are efficiently incorporated into the 
NuA4 complex. Eaf1-HA was immunoprecipitated with an 
anti-HA antibody, and the immunoprecipitate analyzed for 
the presence of Tra1. The levels of Eaf1 and Tra1 in the 
input extract are shown.  
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Figure 1.2.6 
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A 
B 
Figure 1.2.6. Gal4 and Tra1 bind cooperatively to the 
GAL1 promoter. (A) ChIP assay monitoring recruitment of 
Tra1, Spt20 and Gal4 to the GAL1 and RPS0B promoters 
in strains expressing WT TRA1, tra1-mut1 or tra1-mut8 
and grown in media containing galactose or raffinose. (B) 
ChIP assay monitoring recruitment of Gal4 to the GAL1 
promoter in a WT SPT20 or spt20-∆ strain.  Error bars 
indicate standard deviation.  
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Figure 1.2.7 
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A 
Figure 1.2.7. Schematic diagram of the on/off DNA 
strategy. (A) Schematic diagram of the BiFC-based 
strategy to detect whether the Gal4–Tra1 interaction 
occurs predominantly on or off DNA. (B) Immunoblot 
analysis confirming expression of the LexA(DBD)-
Gal4(AD)-VC fusion protein in strains harboring either 
Tra1-VN or Gal80-VN grown in galactose or raffinose. 
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Figure 1.2.8 
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Figure 1.2.8. Gal4 and Tra1 interaction occurs on the 
promoter. (A) BiFC assay monitoring the interaction 
between Tra1-VN and LexA(DBD)-Gal4(AD)-VC in the 
three yeast strains grown in galactose or raffinose. (B) 
BiFC assay monitoring the interaction between Gal80-VN 
and LexA(DBD)-Gal4(AD)-VC in the three yeast strains 
grown in galactose or raffinose. 
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Figure 1.2.9 
64 
Figure 1.2.9. Gcn4 functionally interacts with the Tra1 
GID mutants. (A) Growth of tra1-mut1 and tra1-mut8 on 
His-lacking media containing or lacking 3-AT. Growth of 
WT TRA1 and gcn4-∆ strains are shown as controls. (B) 
BiFC assay monitoring the interaction between Tra1-VN 
and Gcn4-VC in His-lacking media containing or lacking 3-
AT. 
65 
Figure 1.2.10 
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Figure 1.2.10. The Gal4-interaction site on Tra1 is 
highly selective. (A) qRT-PCR analysis monitoring 
expression of 11 Tra1- and SAGA-dependent genes in 
tra1-ts, spt20-∆, tra1-mut1 and tra1-mut8 strains. Gene 
expression is presented relative to that observed in a WT 
strain, which was set to 1 (indicated by the red line). (B) 
ChIP analysis monitoring binding of Tra1 to the promoters 
of the 11 Tra1- and SAGA-dependent genes. Error bars 
indicate standard deviation.  
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Figure 1.2.11 
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Figure 1.2.11. Tra1 GID mutants can interact with 
various activators. BiFC analysis monitoring the ability of 
WT Tra1, Tra1-mut1 or Tra1-mut8 to interact with various 
activators.  
69 
Figure 1.2.12 
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A 
B 
Figure 1.2.12. Microarray data shows that Tra1 GID 
mutants are Gal4 specific. (A) Scatter plot analyses 
comparing gene expression in a WT TRA1 strain and tra1-
mut1 strain (top) or tra1-mut8 strain (bottom). The red line 
represents no change in gene expression; the blue dotted 
line represents 2-fold down-regulation. Gray circles 
represent all the genes on the array; black circles 
represent genes with a p-value <0.05; red circles 
represent genes with a p-value<0.05 and down-regulated 
more than 2-fold.  (B) qRT-PCR analysis monitoring 
expression of GSC2 and HSP30 in tra1-mut1 and tra1-
mut8 strains relative to that observed in a WT TRA1 strain, 
which was set to 1. Error bars indicate standard deviation. 
71 
 72 
Table 1.2.1. Microarray data comparing gene expression in a tra1-2ts strain relative to a 
wild-type TRA1 strain (p<0.05). 
     
   log 2 fold change  
Probe Gene symbol 120 min 90 min 60 min 
10012_at NA -1.226372245 -1.207768354 -1.088297812 
10154_at IDP2 -1.062025648 -1.397346472 -2.097301878 
10204_at ZRT2 -1.693546497 -1.694102453 -1.9383917 
10238_at BUD20 -1.750503576 -1.795024945 -1.565246542 
10268_at REX2 -1.255752195 -1.164401017 -1.224383784 
10282_at NA -1.531035433 -1.974016187 -1.59479357 
10377_at NA 1.440655369 1.653805439 1.459506989 
10378_at AQY2 1.301360348 1.601900901 1.258684398 
10415_at MMP1 -1.322554037 -1.608306622 -1.401658201 
10478_at PCK1 -1.293644718 -1.282967759 -1.252414073 
10479_at UBP11 -1.300677363 -1.27364203 -1.013231909 
10497_at SIS2 -1.252818834 -1.231091171 -1.300768796 
10501_at ECM4 -1.001039214 -1.23475752 -1.336766778 
10601_at SFK1 -1.05344171 -1.275306044 -1.171416271 
10852_at DAN1 1.758400415 2.591673792 1.547578953 
10858_s_at THI11 1.214394359 1.395405163 1.350608614 
10954_at LIA1 -1.375695121 -1.642771735 -1.345510776 
11127_at ALB1 -1.325608385 -1.34043061 -1.079525381 
11133_at NCA3 -2.016193799 -2.416885115 -2.163019521 
11177_at FMP33 -1.535237707 -1.29764351 -1.396321813 
11226_at ACO2 1.692816942 1.418572159 1.657043875 
11228_at PHO90 -1.132894771 -1.102094894 -1.165011219 
11260_at OPT1 -1.598875666 -1.628453295 -1.204435409 
11262_s_at PHO11 -1.49630264 -2.016522899 -2.104202627 
11342_at MAK16 -1.056651274 -1.432647125 -1.05656865 
11370_at CYC3 -1.369717708 -1.259428941 -1.08470426 
11389_at ECM1 -1.634960648 -1.714500625 -1.435056855 
3189_i_at COS8 1.673309659 2.025539479 1.884785592 
3259_at NA 1.316981342 1.612948588 1.406599971 
3316_f_at NA 1.184817697 1.347626442 1.392113641 
3358_f_at NA 1.250214504 1.045026222 1.015535932 
3361_f_at NA 1.415801349 1.677852533 1.188172238 
3368_f_at NA 1.192894452 1.131515 1.167871189 
3371_f_at NA 1.893949049 1.848916649 1.074171085 
3372_f_at NA 1.252031885 1.372837615 1.53997973 
3418_f_at NA 1.650029693 1.783416026 1.129191255 
3438_f_at NA 1.153403486 1.474104928 1.406412669 
3476_f_at NA 1.219314979 1.770233827 1.237017432 
3479_f_at NA 1.13734296 1.160289726 1.200664265 
3482_f_at NA 1.697940527 1.857024486 1.246425058 
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3491_f_at NA 2.01701709 1.80687404 1.283049356 
3508_f_at NA 1.199963494 1.10408395 1.007203658 
3514_f_at NA 1.4641883 1.789969773 1.260490591 
3548_s_at NA 1.649591911 1.831869171 1.628764795 
3563_s_at NA 1.404690762 1.357392858 1.270205922 
3594_f_at NA 1.687428704 1.691750573 1.144044298 
3598_f_at NA 1.302151446 1.464556019 1.327377947 
3645_f_at NA 1.058435983 1.122623103 1.085881394 
3687_f_at NA 1.195607967 1.082197877 1.089775105 
3695_f_at NA 1.123799689 1.050095761 1.086556152 
3707_f_at NA 1.196868317 1.84150666 1.214973265 
3709_f_at NA 1.583758884 1.839268552 1.184649556 
3716_f_at NA 1.517062975 1.328377265 1.509759953 
3758_f_at NA 1.583597896 1.781075676 1.193950851 
3764_s_at NA 2.481400306 2.14278409 1.068471933 
3766_s_at NA 2.381487663 2.310779975 1.239327073 
3767_s_at NA 2.069032787 2.49199005 1.105300263 
3769_s_at NA 1.232606256 2.234937299 1.216994864 
3794_f_at NA 1.016381195 1.784031442 1.131791624 
3803_f_at NA 1.225986232 1.54525296 1.449226313 
3813_f_at NA 2.058513645 1.716623277 1.342865844 
3814_f_at NA 1.343798436 1.034031015 1.192923085 
3821_f_at NA 2.11747248 1.383283141 1.352090785 
3827_f_at NA 1.15195968 1.485584325 1.320939804 
3840_f_at NA 1.31947678 1.899737437 1.166644167 
3867_s_at NA 1.530869411 1.728419633 1.514660293 
3884_f_at NA 1.7451141 1.632430561 1.227354629 
3924_f_at NA 1.04279452 1.878273994 1.158755642 
4070_at LYS1 1.650724845 1.979292924 1.901143433 
4109_at BAR1 2.269907778 1.632377873 1.151711513 
4385_at SPL2 -2.963481901 -3.967203495 -3.216817334 
4386_at ARO9 1.881736181 1.938215698 1.815695735 
4390_at NA -1.07971541 -1.545567189 -1.026451368 
4425_at GAR1 -1.025980243 -1.380629771 -1.142676877 
4428_at HXT4 -1.152164879 -1.062658621 -1.222481608 
4506_at NA -1.782036847 -1.653810522 -1.49785359 
4561_s_at NA 1.318713765 1.358559904 1.283820774 
4583_at SNF6 -1.160956469 -1.327787652 -1.123321353 
4584_at RIM4 1.83492348 1.851553314 1.036397929 
4801_at HIP1 -1.573368309 -1.378332661 -1.065595404 
4813_at NA 1.455183565 1.57618898 1.392299632 
4832_at ATF2 1.204774527 1.078300867 1.067023028 
4842_at BTN2 2.087277044 1.61624537 1.335585976 
4856_at CYS4 -1.13283771 -1.44113781 -1.287177133 
4884_i_at TPO2 1.649076161 1.617706435 1.610188624 
4961_at NA -2.408236232 -3.175988828 -2.509424446 
4994_at NA -1.407296483 -1.332803497 -1.34130352 
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5030_at AGA2 1.565750381 1.279898565 1.194119501 
5073_at DBP3 -1.753055449 -1.630129836 -1.137786371 
5418_at NA 1.222144693 1.18106564 1.249299795 
5553_at BUR6 1.302064445 1.366792201 1.277357579 
5566_at NSA2 -1.71226706 -1.706840852 -1.062014311 
5626_at RAD51 -1.996859608 -2.106117223 -1.809696074 
5654_at SER3 2.023708952 2.043562387 1.518183429 
5669_g_at FCY2 -1.553462513 -1.716628852 -1.112283902 
5774_at PRB1 1.062843303 1.223606984 1.016633859 
5807_at NA 1.114135951 1.407971005 1.332776314 
5927_at STP4 -1.229512878 -1.320963511 -1.096955696 
5940_at EMI2 -1.291517468 -1.303423682 -1.643470032 
6020_r_at MFA1 1.898381709 1.514081909 1.540448747 
6049_at UTP5 -1.162193042 -1.237781251 -1.117126423 
6077_at ARO10 2.308300344 2.449547721 2.053347253 
6100_at VID21 -1.182472328 -1.355770088 -1.097637966 
6140_at SUM1 -1.272076063 -1.476580474 -1.061554989 
6201_at PHM6 -1.032407245 -1.501811996 -1.069264226 
6225_at SWM1 -1.008429008 -1.308110429 -1.126135694 
6547_at LHP1 -1.411653576 -1.797606056 -1.278970296 
6549_at KNH1 -1.275016056 -1.215475496 -1.462990771 
6597_at LYS21 1.116486658 1.013240983 1.277301307 
6598_at STF1 -1.656991103 -1.778303083 -1.675129689 
6803_at NA -1.602812585 -1.749766965 -1.155203598 
6847_g_at NA -1.530738573 -1.673350898 -1.103803499 
6896_at GFD2 -1.445552695 -1.591454003 -1.222336991 
7041_s_at REI1 -1.401543984 -1.147939236 -1.010736831 
7069_at PHO89 -2.503977896 -2.767795659 -2.860615012 
7141_at SWC5 -1.048700677 -1.281535063 -1.033660575 
7314_at ZTA1 -1.17062068 -1.478569392 -1.677063425 
7321_at NA -1.251903099 -1.551365772 -1.266507207 
7334_at FUR4 -1.078044562 -1.698202099 -1.2813895 
7342_at CDS1 -1.670652184 -1.435031 -1.118520787 
7348_at HMT1 -1.391186039 -1.663279486 -1.30016823 
7413_at URA7 -1.053633004 -1.352299477 -1.133564762 
7476_at NA 1.085936664 1.059971876 1.067810269 
7480_at SRO77 1.185588893 1.303254457 1.375337017 
7581_at DPM1 -1.152418059 -1.276581928 -1.134475204 
7587_at NOC4 -1.437844264 -1.328762466 -1.040177587 
7705_at TIF5 -1.244558998 -1.165681119 -1.026684255 
7762_at RPA135 -1.124629988 -1.380771839 -1.301632455 
7779_at VTC3 -1.032394156 -1.440360856 -1.133699116 
7842_at NOG1 -1.037288051 -1.167197447 -1.242620155 
7968_at PRM3 1.009103304 1.562059867 1.305429901 
8004_at RBD2 -1.263894032 -1.622639403 -1.421099628 
8056_at NA 1.325978148 1.114167905 1.050726373 
8161_at PRE10 -1.103490156 -1.114015107 -1.039912497 
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8186_at NA -1.212722769 -1.518279607 -1.308317842 
8203_at VTS1 -1.352692379 -1.523772776 -1.243778792 
8241_at MCH5 -1.979615186 -1.857201354 -1.98965766 
8294_at TPO4 1.05295604 1.415287096 1.115166897 
8380_at GAC1 -1.117067866 -1.254129824 -1.399384206 
8387_at GSP2 -1.011384844 -1.205741659 -1.155062716 
8392_at PNO1 -1.218703267 -1.608700345 -1.328932841 
8445_at LEU9 -1.259761381 -1.553940362 -1.19576111 
8459_at BUD21 -1.256649017 -1.315002726 -1.02981905 
8473_at TMA46 -1.306530465 -1.713773351 -1.463901523 
8505_at HMS1 1.193320725 1.688812373 1.12109662 
8522_at RSB1 -1.329883044 -1.429946965 -1.258654409 
8650_at TRM10 -1.274527458 -1.639366951 -1.290153472 
8683_at GRE2 -1.119489139 -1.363424375 -1.258363188 
8714_at NA 2.212995366 1.194655247 1.236773664 
8808_at LYS9 2.244712898 2.274634949 2.957207553 
8811_at NOG2 -1.146876988 -1.314533053 -1.096270779 
8929_at NA -2.277537975 -2.086489943 -2.406972879 
8981_at RPS7B -1.475543515 -1.565764084 -1.123391523 
9023_at MFA2 1.509525881 1.389804511 1.318109629 
9027_at AAH1 -2.286343878 -2.467192932 -2.073835226 
9032_at IPI3 -1.070736902 -1.189154601 -1.160922076 
9068_at DUG3 -1.142812885 -1.390121488 -1.027935402 
9150_at PCL1 1.318949524 1.749086757 1.643209794 
9193_at NA 2.34707451 2.294445897 1.026687324 
9309_at ADH2 -1.600901037 -2.012313222 -1.740172961 
9339_at HAS1 -1.35700518 -1.321860344 -1.19658027 
9452_at RGM1 -2.300959152 -2.199347063 -1.83996093 
9515_at NA -1.150737949 -1.009873126 -1.276454584 
9545_at NA -1.186881424 -1.077135163 -1.378960759 
9637_at ERG5 1.322483728 1.219480714 1.038951437 
9760_at PGA3 -1.131001678 -1.365484033 -1.433424088 
9762_at PHO84 -1.426957046 -1.312848521 -1.848028623 
9764_at GTR1 -1.078301943 -1.335501187 -1.25391772 
9774_at DAT1 -1.461455646 -1.498636278 -1.247005569 
9853_at FPR4 -1.213093437 -1.283012062 -1.060745604 
9868_at COX19 -1.820645205 -2.044719937 -1.498669773 
9885_at CAR2 1.705506715 1.773749023 1.340872619 
9898_at NA -1.247535322 -1.57140508 -1.131618907 
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Table 1.2.2. List of the top 20 genes most affected by Tra1 inactivation, as 
assessed by expression profiling. For those genes also affected by SAGA 
inactivation, the predicted activators are listed. 
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Gene Function Fold 
down-
regul
ation 
Putativ
e 
activat
ors 
SPL2 Suppressor of plc1 deletion; downregulates low-affinity 
phosphate transport during phosphate limitation 
9.30 Aro80, 
Cbf1; 
Pho4; 
Cbf1, 
Pho4, 
Pho2 
PHO89 Involved in phosphate metabolism; Na+/Pi co-transporter; 
transcription regulated by Pho4 
7.26 Pho4; 
Pho4, 
Aft2 
YGR035C Unknown; transcription activated by Yrm1 and Yrr1 5.69  
YNL058C Unknown 5.30 Ndd1, 
Mcm1; 
Fkh2, 
Mcm1, 
Ndd1 
NCA3 Nuclear control of ATPase; functions with Nca2 to regulate 
mitochondrial expression of F0-F1 ATP synthase subunits 
4.48  
PHO11 Involved in phosphate metabolism; acid phosphatase; 
phosphate starvation-induced transcription coordinately 
regulated by Pho4 and Pho2 
4.30 Pho4  
IDP2 Cytosolic NADP-specific isocitrate dehydrogenase;  4.28  
AAH1 Adenine aminohydrolase; transcriptionally regulated by 
nutrient levels and growth phase 
4.21  
MCH5 Riboflavin transporter 3.97 Put3  
ZRT2 Zinc-regulated transporter; transcription induced under low-
zinc conditions by Zap1 
3.83 Zap1 
PHO84 Involved in phosphate metabolism; high-affinity inorganic 
phosphate transporter; regulated by Pho4 and Spt7 
3.60 Pho4; 
Cbf1, 
Pho4 
RGM1 Putative transcriptional repressor with proline-rich zinc 
fingers 
3.58 Reb1 
RAD51 Strand exchange protein involved in recombinational repair 
of double-strand breaks 
3.50 Mbp1, 
Swi6; 
Swi6 
ADH2 Glucose-repressible alcohol dehydrogenase; 
transcriptionally regulated by Adr1 
3.34  
SOL4 Suppressor of Los1-1; 6-phosphogluconolactonase 3.23  
ZTA1 Zeta-crystallin; NADPH-dependent quinone reductase 3.20  
STF1 Stabilizing factor; involved in regulation of the mitochondrial 
F1-F0 ATP synthase 
3.19  
EMI2 Early meiotic induction; required for transcriptional 
induction of early meiotic-specific transcription factor IME1 
3.12  
RFU1 Inhibits Doa4 deubiquitinating activity 3.02  
BUD20 Involved in bud-site selection 2.96  
 78 
 
Table 1.2.3. Microarray data comparing gene expression in a tra1-
mut1 strain relative to a wild-type TRA1 strain (p<0.05). 
     
 ID Gene symbol Fold change P value 
2595 3310_s_at YDR034C-A -1.207130626 0.001779359 
1545 2207_s_at YGR032W -1.19256344 0.012666811 
3189 3913_s_at YAR010C  -1.013557778 0.005681208 
6130 6854_at YCR021C -1.005050451 0.000142935 
4174 4898_at YGR108W -0.882156111 0.000596586 
2272 2944_g_at YLL021W -0.874190892 0.003812645 
1544 2206_g_at YGR032W -0.872542119 0.00423667 
8980 9704_at YML052W -0.852927463 0.001119004 
6217 6941_s_at YER190C-A  -0.851942748 0.007222219 
5203 5927_at YDL048C -0.84978062 0.002388645 
2504 3187_s_at YBL111C  -0.84015179 0.073767104 
3468 4192_at YIL119C -0.827467305 0.007772781 
3225 3949_i_at YNL044W -0.817149365 0.01218005 
6832 7556_at YPL189C-A -0.812754741 0.000632008 
2298 2970_s_at YKL182W -0.804534336 0.029141472 
70 10069_f_at YLR264W -0.798251776 0.017974932 
4698 5422_s_at YER190C-A -0.783115415 0.001070263 
6041 6765_at YCL048W-A -0.772422209 0.005972537 
69 10068_i_at YLR264W -0.762286462 0.089983193 
5600 6324_g_at YDR133C -0.739842079 0.016506907 
9144 9868_at YLL018C-A -0.718216349 0.098525152 
2164 2836_g_at YLR342W -0.704534724 0.085787013 
4896 5620_at YER091C -0.700606395 0.030026657 
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2948 3672_f_at YBL005W-B -0.67181392 0.004216251 
8622 9346_at YMR295C -0.670228666 0.033400865 
7107 7831_at YPL058C -0.667407491 0.096374758 
757 10756_at YKL163W -0.665228757 0.093656654 
2292 2964_at YKL182W -0.66111955 0.035734882 
3668 4392_at YHR143W -0.657233394 0.035233362 
7836 8560_at YOL002C -0.643088742 0.000753064 
4310 5034_at YGL028C -0.639647293 0.080791361 
8129 8853_at YNR005C -0.637146572 0.004837066 
1999 2666_s_at YNL054W -0.63380518 0.024161365 
4820 5544_at YER150W -0.630562676 0.011902742 
3856 4580_at YHL028W -0.627175751 0.002473332 
4119 4843_at YGR143W -0.621938131 0.017701583 
3191 3915_s_at YAR009C  -0.619467852 0.006385464 
5331 6055_at YDR404C -0.618070705 0.015048041 
1976 2643_s_at YOR153W -0.617999736 0.043771507 
8172 8896_at YNL046W -0.614783895 0.001163966 
1124 11123_at YJL079C -0.613590464 0.019653135 
3611 4335_at YHR175W -0.610404855 0.039227401 
5193 5917_at YDR538W -0.606220723 0.067066862 
5148 5872_at YDR374W-A -0.604194051 0.011629082 
3519 4243_at YIL158W -0.603320387 0.013139729 
7798 8522_at YOR049C -0.59964098 0.001705804 
3455 4179_at YIL087C -0.595911291 0.00460624 
3340 4064_at YIR028W -0.592191668 0.003179717 
5756 6480_at YDR019C -0.590975313 0.010036226 
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Table 1.2.4. Microarray data comparing gene expression in a tra1-mut8 
strain relative to a wild-type TRA1 strain (p<0.05). 
     
 ID Gene symbol Fold change P value 
2595 3310_s_at YDR034C-A -1.097067224 0.002980552 
9145 9869_at YLR264C-A -0.922627325 0.08557862 
6130 6854_at YCR021C -0.895472494 0.000289464 
6217 6941_s_at YER190C-A  -0.804113967 0.009515161 
4160 4884_i_at YGR138C -0.768574006 0.000623581 
3189 3913_s_at YAR010C  -0.729111841 0.025169612 
5148 5872_at YDR374W-A -0.666964525 0.00730186 
7836 8560_at YOL002C -0.666094003 0.000613788 
3340 4064_at YIR028W -0.651389945 0.001906604 
123 10122_at YLR230W -0.63627118 0.023959236 
5203 5927_at YDL048C -0.613805619 0.012079149 
431 10430_at YKL183C-A -0.609352353 0.056935467 
388 10387_at YLL044W -0.601495203 0.042955871 
5297 6021_f_at YDR461W -0.587224505 0.007250929 
 
 
 
 
 
 
 81 
Table 1.2.5. List of yeast strains used in this study. 
 
Strain Genotype Reference 
FY23 MATa leu2∆1 trp1∆63 ura3-52 Winston 1995 
YDA352 MATa leu2∆1 trp1∆63 ura3-52 spt20::URA3 This study 
BY4741 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 Giaever 2002 
LLY074 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 TRA1-VN This study 
LLY071 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 VN-TRA1 This study 
BY4742 MATα his3∆1 leu2∆0 lys2∆0 ura3∆0 Giaever 2002 
LLY080 MATα his3∆1 leu2∆0 lys2∆0 ura3∆0 GAL4-VC This study 
LLY082 MATα his3∆1 leu2∆0 lys2∆0 ura3∆0 GCN4-VC This study 
MDC1 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::HIS3+[TRA1/CEN/LEU2]  
Kulesza 2002 
MDC3 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::HIS3+[tra1-2ts/CEN/LEU2]  
Kulesza 2002 
LLY154 MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::HIS3+[myc-TRA1/CEN/URA3] 
This study 
LLY129 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::HIS3 EAF1-HA+[myc-TRA1/CEN/URA3] This study 
LLY131 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::HIS3 SPT20-HA+[myc-TRA1/CEN/URA3] This study 
LLY197 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::LEU2+[myc-TRA1/CEN/URA3] 
This study 
LLY210 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::LEU2+[myc-VN-TRA1/URA3/CEN] 
This study 
LLY240 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::LEU2 GAL4-VC+[myc-TRA1/CEN/URA3] 
This study 
LLY241 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::LEU2 ZAP1-VC+[myc-TRA1/CEN/URA3] 
This study 
LLY242 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::LEU2 CBF1-VC+[myc-TRA1/CEN/URA3] 
This study 
LLY238 MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 This study 
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tra1::LEU2 CIN5-VC+[myc-TRA1/CEN/URA3] 
LLY245 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::LEU2 REB1-VC+[myc-TRA1/CEN/URA3] 
This study 
LLY246 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::LEU2 MCM1-VC+[myc-TRA1/CEN/URA3] 
This study 
LLY247 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::LEU2 RAP1-VC+[myc-TRA1/CEN/URA3] 
This study 
LLY278 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::LEU2 GCN4-VC+[myc-TRA1/CEN/URA3] 
This study 
LLY279 
MATa ura3-52 lys2-801 ade2-101 trp1∆63 his3∆200 leu2∆1 
tra1::LEU2 FKH2-VC+[myc-TRA1/CEN/URA3] 
This study 
W303 
MATa leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-
11,15 
Veal 2003 
LLY326 
MATa leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-
11,15 GAL80-VN 
This study 
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Table 1.2.6. Primer sequences for quantitative real-time RT-PCR (qRT-PCR) 
analysis, chromatin immunoprecipitation (ChIP) and yeast strain 
construction. 
 
qRT-PCR 
Gene Forward or Reverse Sequence (5’   3’) 
AAH1 Forward CGGTCGAGGAATTAAACGAA 
 Reverse CCACGCCAAATCAAAGAAAT 
ADH2 Forward ACTACGCCGGTATCAAATGG 
 Reverse TCGTGGGTGTAACCAGACAA 
GAL1 Forward GGATCGAGCACGAATAAAGG 
 Reverse ATTCAATATCGCCGTTCCAG 
GAL3 Forward ACCCTTAGTAGGTGCGCAGA 
 Reverse GCGCAAGTAAATGCAGATGA 
GSC2 Forward GGTACAGCACCGGTTTAGGA 
 Reverse AAACAAAATCCGCTGCAAAC 
HSP30  Forward CTAATTGCAGTCAGCCGTGA 
 Reverse TCCGTAGCATGGTGATGAGA 
MCH5 Forward TCGCTACCGCCAACTCTACT 
 Reverse TAGTGGGCGGGAACACTTAC 
PHO11 Forward GTGATTTGCCGGAAAGTTGT 
 Reverse TTTTGGCTTTGCTGACAGTG 
PHO84 Forward TCTGCAAACCACTGTTGCTC 
 Reverse CACCACCGATACCAATACCC 
PHO89 Forward AGGCGCAAGAGTTTCTGGTA 
 Reverse ACCAACAAGACGAGCCAATC 
RAD51 Forward AGATATTGAGGCCACCAACG 
 Reverse AGGCAGCTTCATCGTATGCT 
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RPS5 Forward ACTGACCAAAACCCAATCCA 
 Reverse TTGACGTCTAGCAGCACCAC 
RPS0B Forward CAATCGCCGGTAGATTCACT 
 Reverse GGCCTGAGCGTCTAATCTTG 
RGM1 Forward CTCCTGCTAGCCCACAAGAC 
 Reverse GCAATGGTATGGGAGCAGAT 
SPL2 Forward GGTCACCAGCATAAGGGAAG 
 Reverse TTGAGCCTCCTGCACTCTTT 
YNL058C Forward CCAAGTCCCTTCCATCGTTA 
 Reverse CTGCTGTAGATGGGGGTGTT 
ZRT2 Forward AAAAAGAACCCGGCTCAAAT 
 Reverse CATGGGAACTGGTTGGAACT 
 
ChIP 
Gene Forward or Reverse Sequence (5’   3’) 
AAH1 Forward TTGCAAATTTTCATCGCTTA 
 Reverse ATGCGATGAGGTCAGTTTCC 
ADH2 Forward AACGGCTTTCGCTCATAAAA 
 Reverse CCAAAAAGTGAACCCCATTT 
GAL1 Forward CGTTCCTGAAACGCAGATGT 
 Reverse GCCAGGTTACTGCCAATTTT 
MCH5 Forward CCAAAGCGCAGTATTCAACC 
 Reverse TTCCATCTTTTCCCTCGTGT 
PHO11 Forward TACTGGGAGCAGGAGTTGCT 
 Reverse AAAAACAAAACCGCATCACC 
PHO84 Forward TGAAGTCATCTCCGGGTAGTG 
 Reverse GAGGCGGTTAATCAATGAAAA 
PHO89 Forward AAGGATCCAAAGTGGCTGTG 
 Reverse CAGCACGTGGGAGACAAATA 
 85 
RAD51 Forward TGCACCACTACCGTTCTTCA 
 Reverse GGGTAACGAAGTGTGGCCTA 
RGM1 Forward AGAATTTGCTCAAGCCCTCA 
 Reverse CGCCTTTTATAGTGCCCATC 
RPS0B Forward TGGGCATTACGTTTTCAACA 
 Reverse TGTCATGAATGCATGGGTTT 
SPL2 Forward TGCCCATGGGAAGTCATAGT 
 Reverse CTCTCTTTTCCCACGTGCTC 
YNL058C Forward TTGACAAGGTATGAGTCTAGTTGATT 
 Reverse CATGAAACCCTTAATATGATTTCC 
ZRT2 Forward GGTTATATGCGACTCCTTCTCG 
 Reverse CGGTCTAACCAACAGGGTGT 
 
Yeast strain construction 
Genomic tagging 
Gene Forward or 
Reverse 
Sequence (5’   3’) 
CBF1-VC Forward GAAACAAGAGAACGAAAGAAAAAGCACTAG
GAGCGATAATCCACATGAGGCTGATTACAA
GGACGACGATGACAAGGGTCGACGGATCCC
CGGGTT 
 Reverse ACGCAGATACATAGGGAGACTCGAAATACAT
TTAGCTATCTATTTTTAACTCTCGATGAATTC
GAGCTCGTT 
CIN5-VC Forward AAACAGTGAATTGAAAAAAATGATTGAATCA
TTAAAGTCGAAATTAAAAGAAGATTACAAGG
ACGACGATGACAAGGGTCGACGGATCCCCG
GGTT 
 Reverse TGTGCTTTGAAAACTTTTAAGATGTTACTAGT
ACTAATAATTATTCATTATTTCGATGAATTCG
AGCTCGTT 
FKH2-VC Forward CAAGGAACTAATACTAGATACGGATGGTGCA
AAGATCAGTATTATCAACAACGATTACAAGG
ACGACGATGACAAGGGTCGACGGATCCCCG
GGTT 
 Reverse AGCCATTTCTCATTCATTTCTTTAGTCTTAGT
GATTCACCTTGTTTCTTGTCTCGATGAATTC
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GAGCTCGTT 
GAL4-VC Forward ATGGATGATGTATATAACTATCTATTCGATGA
TGAAGATACCCCACCAAACCCAAAAAAAGAG
GGTCGACGGATCCCCGGGTT 
 Reverse TGAGATGGTGCACGATGCACAGTTGAAGTG
AACTTGCGGGGTTTTTCAGTATCTACGATTC
ATTTCGATGAATTCGAGCTCGTT 
GAL80-
VN 
Forward TTAATCGAGAGCGTTTATAAAAGTAACATGA
TGGGCTCCACATTAAACGTTAGCAATATCTC
GCATTATAGTTTAGGTCGACGGATCCCCGG
GTT 
 Reverse TTACATAGATATATACTCAGTATTCGTTTTTA
TAACGTTCGCTGCACTGGGGGCCAAGCACA
GGGCAAGATGCTTTCGATGAATTCGAGCTC
GTT 
GCN4-VC Forward TCGAAAAATTATCACTTGGAAAATGAGGTTG
CCAGATTAAAGAAATTAGTTGGCGAACGCC
GGATCCCCGGGTTAATTAA 
 Reverse TCGAAAAATTATCACTTGGAAAATGAGGTTG
CCAGATTAAAGAAATTAGTTGGCGAACGCC
GGATCCCCGGGTTAATTAA 
MCM1-VC Forward TGCTGCCTACCAACAATACTTTCAAGAACCG
CAACAAGGCCAATACGAACAGAAATTGATCT
CTGAAGAAGACTTGGGTCGACGGATCCCCG
GGTT 
 Reverse AGCTTTTTCCTCTTAATGCTCGTCTATGAATT
ATATACGGAAATCGATAAGATCGATGAATTC
GAGCTCGTT 
RAP1-VC Forward TGGAACTGGTAGAATGGAAATGAGGAAAAG
ATTTTTTGAGAAGGACCTGTTAGATTACAAG
GACGACGATGACAAGGGTCGACGGATCCCC
GGGTT 
 Reverse TGAAATAAAGGAGTAAAATAAGTTAAACAAT
GATGTTACTTAATTCAATTACTCGATGAATTC
GAGCTCGTT 
REB1-VC Forward GCTAGTTGATTATTTTAGCTCCAATATTTCAA
TGAAAACAGAAAATGAACAGAAATTGATCTC
TGAAGAAGACTTGGGTCGACGGATCCCCGG
GTT 
 Reverse CAAACATTATTGAGTTTTTCGCTTTCACCAAT
TATATTTTCCGGAATCGATGAATTCGAGCTC
GTT 
TRA1-VN Forward CCTAGACTGTATTGGCAGCGCTGTCAGTCC
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AAGAAACTTAGCAAGAACAGACGTGAACTTC
ATGCCATGGTTCGGTCGACGGATCCCCGGG
TT 
 Reverse ATTTTTTGAGGCTTTCTCTACCTTCATTAAAT
ACAGAGAAAAGGCCGGAAACTAACCCATGT
ATCAGCTTCGATGAATTCGAGCTCGTT 
VN-TRA1 Forward CATAAAGAAGATTAAATTCAGAGAAGATCTA
TCACACGATATCTCCATAGTTACAAAGAATA
CCGCATTTTGCCGGAATTCGAGCTCGTTTAA
AC 
 Reverse AGTGGCATCATCATCGCGAAACCTACTGGC
GAATTGCTCGATCTGCTCAGTGAGTGACATA
GTACCACCAGAACCCTCGATGTTGTGGCGG
ATC 
ZAP1-VC Forward AAAATTGAACTCACAGAAAGTGAAATGCGCA
TTGGAAAGAAAACCATATTTAGATTACAAGG
ACGACGATGACAAGGGTCGACGGATCCCCG
GGTT 
 Reverse TTTATGTGATCCTGAAAACCGCCCTTCTTAC
GTTGGACCATGATGATCACATTCGATGAATT
CGAGCTCGTT 
 
Confirmation of genomic tagging 
Gene Forward or 
Reverse 
Sequence (5’   3’) 
CBF1-VC Forward GCAGGAAGAACTGGGAAATG 
CIN5-VC Forward AAAATCGAAGCGCACAAAAG 
FKH2-VC Forward ATAGCGGAGGCAACAAGAGA 
GAL4-VC Forward CACAACCAATTGCCTCCTCT 
GAL80-VN Forward CTAGAGCAAACGACTTCCCG 
GCN4-VC Forward AATCCAGTGATCCTGCTGCT 
MCM1-VC Forward CAGCAACAAATGTCACAGCA 
RAP1-VC Forward TGTTAATCCTCCTCCCAACG 
REB1-VC Forward TGAAGCCTGGCATGAAATTA 
TRA1-VN Forward GGTTCAAACCAACGTTGACC 
VN-TRA1 Forward CCAGGAGCGCACCATCTTCTTCAA 
 88 
 Reverse TCGTGATTCACCAGATCGTC 
ZAP1-VC Forward TCGCGATTTCAAGTTCTTTG 
VC Reverse TTCTCGTTGGGGTCTTTGCTCAG 
VN Reverse TTGAAGAAGATGGTGCGCTCCTG 
 
Plasmid tagging 
Gene Forward 
or 
Reverse 
Sequence (5’   3’) 
GAL4(AD)
-VC 
Forward ATGGATGATGTATATAACTATCTATTCGATGATGA
AGATACCCCACCAAACCCAAAAAAAGAGGGTCGA
CGGATCCCCGGGTT 
 Reverse AATGAAAGAAATTGAGATGGTGCACGATGCACAG
TTGAAGTGAACTTGCGGGGTTTTTCAGTATCTACG
ATTCATTTCGATGAATTCGAGCTCGTT 
TRA1-VN Forward TCCTAGACTGTATTGGCAGCGCTGTCAGTCCAAG
AAACTTAGCAAGAACAGACGTGAACTTCATGCCAT
GGTTCAGATCCATCGCCACCATGGT 
 Reverse ATGACCATGATTACGCCAAGCGCGCAATTAACCC
TCACTAAAGGGAACAAAAGCTGGAGCTCCTACTC
GATGTTGTGGCGGA 
VN-TRA1 Forward GCGGCCGCATGGTGAGCAAGGGCGAGG 
 Reverse GCGGCCGCCGCGCCCTACTCGATGTTG 
 
Confirmation of plasmid tagging 
Gene Forward or 
Reverse 
Sequence (5’   3’) 
GAL4)AD)-VC Forward CACAACCAATTGCCTCCTCT 
 Reverse TTCTCGTTGGGGTCTTTGCTCAG 
TRA1-VN Forward CCAGGAGCGCACCATCTTCTTCAA 
 Reverse GGTGGCGATGGATCTGTTA 
VN-TRA1 Forward GAGCTCAGATCCATCGCCACCATGG 
 Reverse GAGCTCTTAGAAAAACTCATCGAGCATC 
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2.1.1 Cancer 
 
Cancer formation is the transformation of normal cells into highly 
malignant invasive derivatives, via a series of premalignant states (Fearon & 
Vogelstein, 1990).  It involves dynamic genetic changes in the genome in a 
stepwise process, and each step enables precancerous cells to acquire one type 
of growth advantage.  The theory that cancer is a genetic disease was first 
proposed by David von Hansemann in 1890.  Later, in the early twentieth 
century, a zoologist named Theodor Boveri brought up a bold and visionary 
hypothesis that provided the foundation for viewing cancer as a genetic disease. 
He believed that cancer origins from a single cell with genetic alterations and the 
genetic alterations caused by environment stimulation could endow unlimited cell 
growth.  Boveri also proposed the concepts of cell cycle checkpoint, tumor 
suppressor genes and oncogenes.  Many of his predictions are now explained by 
the molecular mechanisms that discovered using modern techniques.  
Although cancer is a complex disease, its initiation and progression have 
several characteristic hallmarks that are shared by almost all types of cancers.  
Weinberg, Pouyssegur, Elledge and their colleagues, summarized the hallmarks 
of cancer and their function in transformation process (Hanahan & Weinberg, 
2000, 2011; Kroemer & Pouyssegur, 2008; Luo et al, 2009).  Hallmarks of cancer 
can be categorized into two classes: “emerging hallmarks”, which initiate or 
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promote transformation progress, and “enabling characteristics”, that are resulted 
from “emerging hallmarks” and are the phenotypes shared by many cancer 
types. “Emerging hallmarks” include: (1) deregulation of growth promoting or 
inhibiting signals, (2) evasion of apoptosis or senescence, (3) unlimited 
replication (bypass cellular crisis), (4) metabolism reprogramming, (5) 
deregulation of angiogenesis switch, (6) avoidance of immune surveillance, (7) 
tissue invasion and metastasis (Hanahan & Weinberg, 2000, 2011; Kroemer & 
Pouyssegur, 2008; Luo et al, 2009).  “Enabling characteristics” are the results of 
genetic alterations and cellular changes from the “emerging hallmarks”.  They 
include: (1) genome instability (DNA damage and DNA replication stress, mitotic 
stress), (2) cellular stress (proteotoxic stress, metabolic stress, oxidative stress), 
(3) inflammatory responses.  Transformation of human cells is a long process of 
accumulation of these cellular alterations, which are caused by alteration or 
deregulation of many genes (Summarized in Figure 2.1.1). The accumulation of 
these changes is more important than their order with respect to one another.  
These genes may have functions that promote the transformation process or 
functions that prevent cells from transformation.  Gaining oncogenic functions 
and losing tumor suppression functions of a normal cell lead to the 
transformation to cancer cell.  
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2.1.2 Oncogene  
History of oncogene discovery 
One hundred years ago, the discovery of Rous sarcoma virus by Dr. 
Peyton Rous opened the field of tumor virology and led to the discovery of first 
oncogene Src and molecular mechanisms of cancer formation (Rous, 1911).  In 
1970s, in an effort to understand the function of viral oncogene Src and Abl, 
Bishop and Hunter groups found that protein phosphorylation was important in 
the transformation process (Levinson et al 1978; Eckhart et al 1979).  The next 
year, the tyrosine kinase receptor oncogene, EGFR (epidermal growth factor 
receptor), was found by Cohen, followed by the discovery of PDGF (platelet-
derived growth factor) by Waterfield and Antoniades (Ushiro and Cohen 1980; 
Waterfield et al 1983; Doolittle et al 1983).  In 1982, Weinberg, Wigler and 
Barbacid groups cloned the first cellular oncogene RAS and discovered a single 
amino-acid change that could constitutively active RAS protein and lead to 
transformation (Shih and Weinberg 1982; Goldfarb et al 1982; Pulciani et al 
1982; Tabin et al 1982; Reddy et al 1982; Taparowsky et al 1982).  Discoveries 
of RAS, EGFR, PDGF together with v-erbB suggest that oncogenes are 
components of the normal growth regulatory machinery.  Later on, many other 
oncogenes were found having functions upstream or downstream of these 
kinases signal transducers.  
The role of oncogene in cancer development  
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Oncogenes initiate and promote transformation during cancer 
development by regulating the “emerging hallmarks” of cancer.  Oncogenes (1) 
allow cells to proliferate in an uncontrolled and unlimited manner that is resistant 
to programmed cell death, (2) adapt the cell metabolism to anaerobic, acidic and 
high stress environment, (3) signal surrounding non-malignant cells to secret 
growth factors, (4) change environment to favor cancer cell growth, (5) protect 
cells from killing by immune response, and (6) promote metastasis to distant 
location. 
Activation of oncogenes  
Proto-oncogenes are genes with normal cellular functions.  They can be 
activated and converted to cancerous oncogenes by mutations or elevated 
expression, which includes epigenetic regulation, gene amplification and 
chromosome translocation.  For example, mutations in RAS, which is a small 
GTPase, can constitutively activate the signaling pathways that lead to cell 
growth and division, independent of extracellular signals (Tabin et al 1982; 
Reddy et al 1982; Taparowsky et al 1982).  Amplification of fibroblast growth 
factor receptor 1 (FGFR1) in lung squamous carcinoma activates MAPK and 
AKT pathways and results in cell proliferation independent of ligand binding (Dutt 
et al 2011; Weiss et al 2010).  BCR-ABL oncogene, resulted from translocation of 
chromosomes 9 and 22, can enhance cell division, inhibit DNA repair and cause 
chronic myeloid leukemia (CML) (Nowell, 1960).  Promoter hypomethylation of 
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BCL-2 gene causes its overexpression in B-cell chronic lymphocytic lymphomas 
(Hanada et al 1993).  
Classification of oncogenes  
Oncogenes can be grouped into seven categories based on their cellular 
functions:  (1) growth factors (e.g. c-Sis); (2) tyrosine kinase receptors (e.g. 
EGFR, FGFR); (3) transcription factors (e.g. MYC); (4) signal transducer, which 
includes cytoplamic tyrosine kinases (e.g. Src family), cytoplasmic 
serine/threonine kinases (e.g. Raf) and signal regulatory proteins (e.g. Ras); (5) 
chromatin remodelers (e.g. ALL1); (6) apoptosis regulators (e.g. Bcl-2 family); 
and (7) microRNAs (e.g. miR-17). 
Receptor tyrosine kinases  
Receptor tyrosine kinase (RTK) is a large family of cell surface receptors.  
It is so called because RTK can catalyze the tyrosines on target proteins by 
transfer the γ phosphate of ATP to hydroxyl groups of tyrosines.  RTK has very 
important cellular functions in regulating cell cycles, migration, metabolism, 
survival, proliferation and differentiation.  The structure, activation and signaling 
of members in RTK family are similar (Hunter, 1998).  Here we use FGFR as an 
example of receptor tyrosine kinases. 
 
2.1.3  FGFR1 
Structure There are five members of the FGF receptors: FGFR1(flg), 
FGFR2(bek, KGFR), FGFR3, FGFR4 and FGFR1L(has no kinase domain). First 
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FGF receptor was designated as fms-like gene (flg) because it was isolated from 
a human endothelial cell cDNA library by hybridizing at relaxed stringency using 
the v-fms oncogene as a probe (Ruta et al 1988).  Further analysis of its 
structure and function revealed that flg was the receptor for acidic FGF (Ruta et 
al 1989). As illustrated in Figure 2.1.2, the structure of FGFR1 consists of an 
extracellular domain (EC), a transmembrane (TM) stretch, a juxtamembrane (JM) 
domain, a kinase domain (KD) and a C-terminal (CT) (Klint, 1999).  Three 
phosphorylation sites, Y653, Y654 and Y730, appear to be involved in the kinase 
regulation.  Phosphorylation of Y766 binds to phospholipase Cr (PLCr).  
Activation  
FGFs are secreted glycoproteins that are sequestered by heparin sulphate 
proteoglycans to the extracellular matrix (HPSGs).  To signal, FGFs are liberated 
from extracellular matrix and bind to cell surface HPSG and FGF receptors 
(Harmer et al 2004, Mohammadi et al 2005).  Crystal structure shows that they 
form a stable 2:2 FGF: FGFR complex stabilized by heparin (Schlessinger, 
2000).  Dimerization of FGFR1 leads to trans-autophosphorylation of their 
cytoplasmic domains (Schlessinger, 1988). Binding of FGF to FGFR stimulates 
tyrosine kinase activity was first discovered in NIH3T3 cells (Coughlin et al 1988).  
In addition, FGFR can also be activated by inhibition of protein tyrosine 
phosphatases, receptor amplification or mutations, independent of ligand binding.  
Signaling  
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Under normal conditions, FGF binding leads to kinase activation, tyrosine 
phosphorylation of residues in the kinase domain and tyrosine phosphorylation of 
the C-terminal tail of FGFR.  The major effector of FGFR is the adaptor protein 
FRS2 (FGFR substrate 2).  FRS2 constitutively associates with FGFR 
juxtamembrane domain independent of its activation and gets phosphorylated on 
several Tyr and Ser/Thr residues following FGFR activation (Ong et al 2000).  
pFRS2 functions as a docking site for Grb2 and activates  MAPK and AKT 
pathway through SOS and Gab1 respectively, and in turn regulates cell 
proliferation and cell survival (Eswarakumar et al 2005; Altomare et al 2005).  
The C-terminal phosphorylation of FGFR phosphorylates and activates 
Phospholipase Cr (PLCr) through its Src homology 2 (SH2) domain (Peters et al 
1992).  Activated PLCr hydrolyses phosphatidylinosito-4,5-biphosphate (PIP2) to 
phosphoatidylinositol-3,4,5-triphosphate (PIP3) and diacylglycerol (DAG), and 
then activate protein kinase C (PKC) and MAPK pathway (Klint et al 1999). 
Oncogenic functions  
Several types of genetic changes of FGFR1 can cause its oncogenic 
function: gene amplification, activating mutations, chromosomal translocations, 
single nucleotide polymorphisms and aberrant splicing.  However, constitutive 
activation by amplification or mutation is the most common in cancer.  Oncogenic 
FGFR1 signaling can cause proliferation, survival, migration, invasion and 
angiogenesis, and has been found in many types of cancers (Table 2.1.1 and 
2.1.2).  FGFR1 amplification, results of chromosome amplification, is the most 
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common genetic alteration in lung squamous carcinoma (~20%) (Weiss et al 
2010; Dutt et al 2011), and one of the most common focal amplification in 
estrogen receptor (ER)-positive breast cancer (10%) (Courjal et al 1997; 
Jacquemier et al 1994; Reis-Filho et al 2006).  Amplification of FGFR1 has also 
been found in oral squamous carcinoma (Freier et al 2007), ovarian cancer 
(Gorringe et al 2007), bladder cancer (Simon et al 2001) and 
rhabodomyosarcoma (Missiaglia et al 2009).  Constitutive active FGFR TDII 
(thanatophoric dysplasia type II) like mutation (FGFR1K656E, FGFR3K650E, 
FGFR4K645E) can activate Stat1 and Stat3 (Hart et al 2000).  
 
2.1.4 Tumor suppressor genes 
Mechanisms of tumor suppressor  
In the 1970s and early 1980s, more and more evidence hinted that there 
is a second type of growth-controlling genes that function to constrain or 
suppress cell proliferation, so called tumor suppressor genes (TSGs).  TSGs 
negatively regulate cancer development by several different mechanisms: (1) 
repressing cell growth signaling pathways and inhibiting cell division, (2) blocking 
cell cycle in response to DNA or cellular damage, (3) initiating programmed cell 
death, (4) promoting cell adhesion to prevent metastasis, (5) functioning in DNA 
repair to reduce the risk of genomic instability.  TSGs can be classified into three 
categories based on their functions: “caretaker”, “gatekeeper” and “landscaper” 
(Kinzler and Vogelstein, 1997; Michor et al., 2004; Ashworth et al, 2011).  
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“Caretaker” genes maintain genome stability and prevent mutation acquisition.  
For example, BRCA1 and BRCA2 play critical roles in DNA repair.  “Gatekeeper” 
genes control cell growth, for example, p53 can induce cell cycle arrest or cell 
death.  “Landscaper” genes control the microenvironment for tumor growth.  For 
example, TSP1 has anti-angiogenesis function therefore cutoff the nutrient 
supply for tumor growth (Volpert et al, 2002).   
History of tumor suppressor gene discovery  
Due to the recessive nature of TSGs, TSGs discovery is more difficult than 
oncogenes.  In early years, people discovered tumor suppressing elements using 
transfer approaches, which deliver intact or fragmented chromosomes, such as 
yeast artificial chromosome (YAC) or bacterial artificial chromosome (BAC), into 
cancer cells to monitor the inhibition of cell growth (Harris et al 1969; Fournier et 
al 1977; Stanbridge, 1976, 1992; Murakami 1995,1998, Todd 1996).  The 
discovery of RB gene, the first tumor suppressor, confirmed the “two-hit 
hypothesis”: cancer is caused by at least two successive mutations, the first hit 
inactivates one allele of a TSG and the second hit results in the loss of the other 
allele (Friend et al 1986, Knudson, 1971).  In cancer cells, loss of heterozygosity 
(LOH) is considered the second hit of the “two-hit hypothesis”.  Single nucleotide 
polymorphism (SNP)-based array was widely used to detect genome-wide copy 
number and LOH status to identify new TSGs.  In early 1980s, fluorescence in 
situ hybridization (FISH) was developed to detect and localize the presence or 
absence of specific DNA sequences, which provided an alternative way to 
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identify TSGs.  However, FISH is only useful to identify genes with known 
sequences and can only test one gene at a time.  In 1990s, comparative genomic 
hybridization (CGH) was developed to analyze the copy number changes of 
TSGs.  However, this approach cannot detect chromosome aberrations, such as 
translocations or inversions.  Many genes are silenced by epigenetic events, 
such as methylation, irrespective of their LOH status in tumors.  During last 
decades, gene expression arrays and promoter methylation arrays were widely 
used in discovering genes that are differentially expressed in cancer cells and 
normal cells, which could be potential TSGs.  
Genome-wide RNAi screen  
The elucidation of the mechanism of RNAi by Mello and Fire in 1998 
spurred an industry of RNAi biotechnology.  RNAi is a naturally occurring gene 
expression regulation mechanism.  In eukaryotes, double stranded interfering 
RNA targets and degrades complementary mRNA, and results in selective gene 
silencing.  By delivering short hairpin RNA (shRNA), the precursor of siRNA, into 
cultured cells, we can knock down a specific gene in very short time and at much 
lower cost, comparing to traditional targeted gene inactivation or knock-out 
techniques.  The development of genome-wide RNA interference (RNAi) library 
made it possible to conduct high throughput loss of function screens for specific 
phenotypes with assistance from statistics and bioinformatics (Paddison et al 
2004; Berns et al 2004).  Pools of shRNA expressing vectors are introduced into 
cells by transfection or infection.  Cells are then selected for certain phenotypes.  
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In positive screens, cells are selected for ability to transform, or induced drug 
resistance, etc.  Transformed cells or surviving cells were then used for DNA 
isolation.  shRNA sequence were amplified by PCR and sequenced.  In negative 
screens, e.g. drug sensitivity, DNA from cell populations from before and after 
drug treatment are isolated, sequenced and compared for gene identification 
(Figure 2.1.3). 
Taking advantage of this technique, many new TSGs were identified.  For 
example, REST is found as a tumor suppressor in breast cancer (Westbrook et al 
2005); Sfrp1, Numb, Mek1 and Angpt2 are tumor suppressors in lymphoma (Bric 
et al 2009); XPO4 is a tumor suppressor for liver cancer (Zender et al 2008, etc).  
From our study, we identified 24 new tumor suppressors for lung squamous 
carcinomas cancer. 
 
2.1.5  Targeting Drug Development 
Besides surgical removal, cancer therapies usually target cancer cells, 
cancer vasculature, the immune system and even the bone marrow.  After 
decades of extensive studies of the molecular basis underpinning cancer 
development, therapeutics targeting the hallmarks of cancer cells have been 
rapidly developed.  In cancer cells, signal transduction pathways are frequently 
altered.  Therefore, many drugs, such as tyrosine and threonine kinase inhibitors, 
are developed directly targeting signal transducting molecules.  Imatinib (Glivec), 
a drug that treats chronic myelocytic leukemia (CML) by inhibiting BCR-ABL, is 
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the first tyrosine kinase inhibitor approved for clinical use (Druker et al 2001).  
Gefitinib and Erlotinib, EGFR inhibitors, are subsequently approved for non-small 
cell lung cancer (NSCLC) treatment (Lynch et al 2004).  However, lung 
squamous cell carcinomas (LSCC) bare a different genetic alternation that is not 
responsive to EGFR inhibitors.  FGFR1 has been found amplified in more than 
20% of LSCC patients. It suggests that FGFR1 can be a potential drug target for 
LSCC treatment.  
Drug development research on FGFR signaling pathway are majorly using 
small-molecule tyrosine kinase inhibitors, but blocking antibodies and ligand-trap 
approaches are also being developed (Table 2.1.3).  Tyrosine kinase inhibitors 
(TKIs) such as PD173074, ponatinib or TKI258 block FGFR signals and reduce 
FRS2 tyrosine phosphorylation, causing the dissociation of Grb2 and therefore 
inhibit ERK and AKT activities.  Blocking antibodies can decrease tumor cell 
proliferation and induce apoptosis same as TKIs, however, it may potentially 
recruit immune effector cells to the tumor and may lead to antibody-dependent 
cellular cytotoxicitiy.  Many small molecule inhibitors of FGFR tyrosine kinase 
activity have been discovered and described in the literature.  Many of these are 
currently in clinical trials in various types of cancers (Table 2.1.3).  Our study 
suggests that the application of FGFR tyrosine kinase inhibitors is not restricted 
in LSCC.  Patients missing FGFR negative regulating TSGs can be selected for 
treatment with FGFR inhibitors.  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Figure 2.1.1. Transformation is a multistep process.  
Genetic or epigenetic alterations in tumor suppressor 
genes or oncogenes lead to the acquiring cancer 
hallmarks.  The accumulation of these changes, rather than 
their order, is most important. 
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Figure 2.1.2.  Schematic structure of FGFR1.  FGFR1 has 
6 domains: (1) Extracellular domain contains three 
immunoglobulin (Ig)-like domains. Some splicing variants 
have two (II and III) Ig-like domains.  (2) Transmembrane 
domain.  (3) Juxtamembrane domain. (4) kinase domain with 
a short kinase insert. (5) C-terminal tail.  
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Figure 2.1.3. Strategy of Pooled RNAi Library Screen.  Pools of 
shRNA expressing vectors are introduced into cells by transfection 
or infection.  Cells are then selected for certain phenotypes.  In  
positive screens, cells are selected for the ability to transform, drug 
resistance etc.  Transformed cells or survived cells were then used 
to isolate DNA.  shRNA sequence were amplified by PCR and 
sequenced.  In negative screens, e.g. drug sensitivity screen, DNA 
from cell populations from before and after drug treatment are 
isolated, sequenced and compared for genes identification. 
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Table 2.1.1. Genetic alterations in FGFR1 and related cancer 
Amplification Lung squamous carcinoma (~20%), breast 
cancer (10%), ovarian cancer (~5%), bladder 
cancer (3%) and rhabodomyosarcoma (3%) 
Courjal 1997, Jacquemier 
1994, Gorringe 2007, Simon 
2001, Missiaglia 2009 
P252S: Melanoma Lin, 2008; Ruhe, 2007 
P252T, V664: Lung cancer Davies, 2005; Greenman, 
2007 
N546K, R576W: Glioblastoma Rand, 2005; Lew, 2009 
K656E: Glioblastoma Network, 2008 
Mutation 
S125L: Breast Greenman, 2007 
Translocation Stem cell leukaeia and lymphoma syndrome 
(or EMS), chronic myeloid leukaemia (rare) 
Xiao 1998, Roumiantsev 2004 
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Table 2.1.2 Altered expression of FGFR1 in cancer 
Cancer type Up-regulated (references) 
Brain Kroemer 2008; Luo 2009; Colotta 2009; Stratton 2009 
Head and 
neck 
Olsen 2004; Zhang 2006; Ornitz 1996; Schlessinger 2000; Lew 2009; Chen 
2007; Mohammadi 1996 
Sarcoma Lu 2008; Parsa 2008; Murakami 2008  
Soft tissue 
sarcoma 
Beenkan 2009; Chin 2006; Toyokawa 2009 
Thyroid Ray 2004; Bernard-Pierrot 2008  
Lung 
Xian 2009, 2005; Reis-Filho 2007; Easton 2007; Hunter 2007; Meyer 2008; 
Turner 2010; Sahadevan 2007; Giri 1999; Hamaguchi 1995; Freeman 2003 
Breast 
Grand 2004; Trudel 2006; Keats 2003; zingone 2010; Cha 2008; Ezzat 2002; 
Itoh 1994; Cha 2009 
Liver Jang 2001 
Pancreas Gartside 2009; Cheng 2009; Knowles 2008; Tomlinson 2007; d’Avis 1998 
Stomach Martinez-Torrecuadrada 2008; Hernanda 2008  
Bladder Roumiantsev 2004, Guasch 2004; Chen 2004, Ren 2009; Demiroglu 2001 
Prostate 
Dphna-Iken 1998; MacArthur 1995; Song 2002; Valta 2008; Maruyama-
Takahashi 2008; Schimada 2005; Wang 1997 
Testis Dellacono 1997 
Colon Memarzadeh 2007 
Uterus Joyce 2009; Abdel-Rahman 2008  
Ovary Darby 2006; Murphy 2010  
Skin Cho 2004; Tannheimer 2000 
Leukaemia/M
PD/lymphoma 
Cho 2007; Fogarty 2007; Knights 2010; Byron 2010; Claudio 2007 
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Table 2.1.3.  Current status of FGFR-targeting therapies 
Drug name Company Activity  Clinical development Reference 
Small molecular tyrosine kinase inhibitors 
SUS402  Selective FGFR inhibitor NA Ropiquet 2000 
PD173074  FGFR, PDGFR and VEGFR inhibitor NA Mohammadi 1998 
Ponatinib(AP24534) Ariad Pharmaceuticals FGFR, BCR-ABL, PDGFR and VEGFR 
inhibitor 
Phase II Joseph 2012 
Cediranib(AZD2171) AstraZeneca FGFR, PDGFR and VEGFR inhibitor Phase I (Gstric, Breast) 
Phase II (Endometrial) 
Takeda 2007, 
Wedge 2005 
Dovitinib(TKI258) Novartis FGFR, PDGFR and VEGFR inhibitor Phase II (Breast, Bladder, 
Myeloma) 
Sarker 2008 
Intedanib(BIBF1120) Boehringer Ingelheim FGFR, PDGFR and VEGFR inhibitor Phase III Hilberg 2008 
Brivanib(BMS-582,664) Bristol-Myer Squibb FGFR and VEGFR inhibitor Phase II (Endometrial, Gastric, 
Bladder) 
Chen 2005;  
Huynh, 2008 
E7080 Eisai FGFR, PDGFR and VEGFR inhibitor Phase I (solid malignancies), 
Phase II (Endometrial) 
Matsui 2008 
TSU-68 (Orantinib) Taiho Pharmaceutical FGFR, PDGFR and VEGFR inhibitor Phase II/III Machida 2005 
AZD4547 Astra Zeneca Pan-FGFR Phase I (solid malignacies), 
Phase I/II (Breast) 
 
BGJ398 Novartis Pan-FGFR Phase I (solid malignancies)  
Masitinib (AB1010) AB Science c-KIT, PDGFR, FGFR3 Phase III (Gastrointestinal 
Stromal Tumors) 
Hahn, 2008 
SU6668 Sugen FGFR, PDGFR, VEFGR2 Phase I (Advanced Solid 
Tumors) 
Fabbro, 2001 
Pazopanib 
(GW786034) 
Glaxo Smith Kline VEGFR, PDGFR, c-KIT, FGFR1/3 Phase III (Metastatic Renal Cell 
Carcinoma) 
Kumar, 2007 
RO438596 Roche VEGFR, PDGFR, FGFR  Marek 2009, 
McDermott, 2005 
FGFR antibodies and FGF ligand traps 
IMC-A1 ImClone FGF1-IIIc-specific antibody NA Sun 2007 
PRO-001 ProChon Biotech FGFR3-specific blocking antibody NA Trudel 2006 
R3Mab Genentech FGFR3-specific antibody NA Qing 2009 
1A6 Genentech FGF19-specifc antibody NA Desnoyers 2008 
FP-1039 Five Prime 
Therapeutics 
FGF ligand trap (multiple FGFs) Phase I (solid malignancies) 
Phase II (endometrial) 
Martinez-
Torrecuadrada 
2005 
(ref: Greulich & Pollock, 2011; Knights & Cook, 2010) 
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CHAPTER II 
 
Identification of Squamous Cell Lung Cancer Tumor 
Suppressor Genes that Negatively Regulate FGFR1 
Signaling 
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Abstract 
A goal of contemporary cancer research is to identify the genes 
responsible for neoplastic transformation.  Here we describe a functional 
genomics approach to discover new tumor suppressor genes (TSGs). Cells that 
are immortalized but non-tumorigenic were stably transduced with pools of short 
hairpin RNAs (shRNAs) and tested for their ability to form tumors in mice. 
ShRNAs in any resulting tumors were identified by sequencing to reveal 
candidate TSGs, which were then validated experimentally and by expression 
analysis of human tumor samples. Using this approach, we identified and 
validated 24 TSGs that were down-regulated in >70% of human lung squamous 
cell carcinomas (LSCCs). Amplification of fibroblast growth factor receptor 1 
(FGFR1), which aberrantly increases FGFR signalling, is the most common 
known genetic alteration in LSCC. Remarkably, we found that 17 of the 24 TSGs 
encode negative regulators of FGFR signalling.  Knockdown of 11 TSGs in 
immortalized human bronchial epithelial cells results in increased total or 
phosphorylated levels of FGFR1 leading to transformation and sensitivity to 
FGFR1 pharmacological inhibition. Our results indicate that many LSCCs without 
FGFR1 amplification or activating mutations may respond to FGFR1 inhibitors 
and in a predictable manner. 
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Introduction 
The conversion of a normal cell to a cancer cell is a stepwise process that 
involves the activation of genes that promote cancer, oncogenes, and the 
inactivation of genes that protect cells from cancer, such as tumor suppressor 
genes (TSGs). A goal of contemporary cancer research is to identify all genes 
responsible for neoplastic transformation. For example, the identification of new 
TSGs has important implications for both diagnosing and treating cancer. 
TSGs are defined by a series of characteristic properties (Weinberg 2006). 
First, TSGs are inactivated in certain human tumor types either by deletion, 
mutation or a transcriptional repression mechanism including epigenetic 
silencing. Epigenetically silenced TSGs bear several hallmarks including 
repressive histone modifications and hypermethylated CpG-rich promoter regions 
(Esteller 2007). Second, inactivation of a TSG in an appropriate cell type 
promotes one or more growth-related properties such as immortalization, 
proliferation, or tumorigenesis. Conversely, over-expression of a TSG in an 
appropriate cell type has one or more growth-suppressive effects such as 
inhibition of cell cycle progression or the induction of apoptosis or senescence. 
One of the ongoing efforts to identify the genes responsible for tumor 
formation is partial or complete sequencing of cancer genomes (Mardis and 
Wilson 2009). Although this approach has and will continue to reveal genes 
involved in tumorigenesis, there are specific challenges for discovery of TSGs 
solely by sequence analysis of cancer genomes. First, the genomes of cancer 
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cells are error-prone (Loeb 2001) and thus many of the mutations found in 
cancer cells are not causally related to the transformed phenotype. Second, as 
mentioned above, in many instances TSGs are inactivated by epigenetic 
silencing rather than a mutational event, and thus would not be identified by 
conventional genome-sequencing methods. 
Fibroblast growth factors receptors (FGFR) are cell surface tyrosine 
kinase receptors for fibroblast growth factors.  They play crucial roles in 
development, cell profleration, survival and migrations.  FGFRs familiy consists 
of four members (FGFR1-4) and one non-catalytic functional protein (FGFR1L).  
FGFR signaling can be activated by (1) ligand induction (2) FGFR amplification 
or activating mutations.  Activation of FGFR1 leads to kinase activation, tyrosine 
phosphorylation of residues in the kinase domain and the C-terminal tail.  The 
major effector of FGFR signaling is the adaptor protein FRS2 (FGFR substrate 
2).  FRS2 is constitutively associated with FGFR independent of its activation 
and gets phosphorylated on several Tyr residues following FGFR activation (Ong 
et al 2000).  pFRS2 functions as a docking site for Grb2 and activates MAPK and 
AKT pathway through SOS and Gab1 respectively, and in turn regulates cell 
proliferation and cell survival (Eswarakumar et al 2005; Altomare et al 2005). The 
C-terminal phosphorylation of FGFR activates protein kinase C (PKC) and MAPK 
pathways by phosphorylating and activating Phospholipase C r (PLCr) through its 
Src homology 2 (SH2) domain (Peters et al 1992; Klint et al 1999). In cancer, 
FGFR signaling pathway is usually constitutively activated by amplification or 
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mutation. Oncogenic FGFR1 signaling can cause proliferation, survival, 
migration, invasion and angiogenesis.  FGFR1 amplification is the most common 
genetic alteration in lung squamous carcinoma (~20%) (Weiss et al 2010; Dutt et 
al 2011), and one of the most common focal amplifications in estrogen receptor 
(ER)-positive breast cancers (10%) (Courjal et al 1997; Jacquemier et al 1994; 
Reis-Filho et al 2006).  Amplification of FGFR1 has also been found in oral 
squamous carcinoma (Freier et al 2007), ovarian cancer (Gorringe et al 2007), 
bladder cancer (Simon et al 2001) and rhabodomyosarcoma (Missiaglia et al 
2009).  Amplification of FGFR1 activates MAPK but not AKT pathway (Weiss et 
al 2010). 
Drug development research on inhibiting FGFR signaling pathway are 
primarily using small-molecule tyrosine kinase inhibitors, but blocking antibodies 
and ligand-trap approaches are also being developed.  Tyrosine kinase inhibitors 
(TKIs) such as PD173074, ponatinib or TKI258 block FGFR signaling and reduce 
FRS2 tyrosine phosphorylations, cause the dissociation of Grb2 and therefore 
decrease in ERK and AKT activity.  
Functional genomics approaches for TSG discovery are highly 
complementary to cancer genome sequencing efforts. In this regard, several 
recent studies have described in vivo RNA interference (RNAi) screens in mice 
that have successfully identified TSGs involved in liver cancer (Zender et al 
2008) and genes that suppress lymphoma progression (Bric 2009, Meacham 
2009). These studies were performed using a limited collection of shRNAs 
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targeting genes that had been previously implicated or suspected to be involved 
in cancer. Here we describe and demonstrate a large-scale RNAi-based 
functional approach for TSG discovery that is unbiased with regard to either the 
genes being targeted or cancer type.  From the screen, we identified 24 TSGs in 
lung squamous carcinoma, suggesting that they can be used as new biomarkers 
in cancer diagnosis.  Among these 24 TSGs, 17 can negatively regulate FGFR1 
signaling pathway and 12 regulate expression or activation levels of the receptor.  
Lung small air way cells are sensitive to FGFR1 inhibitors when knocking down 
individual TSGs.  Therefore, we propose that the application of FGFR1 inhibitor 
can be expanded beyond FGFR1 amplification patients.  Expression level of 
TSGs can be used as marker for drug selection and to predict drug 
responsiveness. 
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RESULTS 
A large-scale shRNA screen for the identification of candidate TSGs 
To identify TSG candidates, we performed a large-scale shRNA screen for 
tumorigenesis in mice, which is summarized in Figure. 2.2.1.A and is discussed 
below. We used NIH 3T3 fibroblasts, which are immortalized but not transformed 
and can be rendered tumorigenic by a wide range of oncogenic events (Stacey 
and Kung, 1984; Ikawa et al 1988, Smith et al 1990; Velu et al 1987; Di Fiore et 
al 1987).  
Before initiating the primary screen, we performed a reconstruction 
experiment to determine a minimal number of transformed NIH 3T3 cells required 
for tumorigenesis in our xenograft system. In this approach, 1000, 100 or no 
Kras-transformed NIH 3T3 cells were added to non-transformed NIH 3T3 cells to 
achieve a total of 1x106 cells, which were then injected into the flanks of nude 
mice. As expected, no tumors formed in the sample lacking Kras NIH 3T3 cells. 
However, tumors were observed in samples containing either 100 or 1000 Kras 
NIH 3T3 cells (Figure. 2.2.1.B), indicating that 100 transformed NIH 3T3 cells 
(and likely fewer) are sufficient to initiate a detectable tumor in a mouse 
xenograft.  
For the primary screen, a mouse shRNA library comprising 62,400 
shRNAs directed against ~28,000 genes (Silva et al 2005) was divided into 10 
pools, which were packaged into retrovirus particles and used to stably transduce 
mouse NIH 3T3 cells. For each of the 10 stable cell populations, 1x106 cells were 
  135 
injected subcutaneously into the flank of a nude mouse. Thus, each of the 6240 
shRNAs in each pool was present in ~160 cells, which is greater than the 100 
transformed NIH 3T3 cells found in the reconstruction experiment to be required 
for tumor formation. We found that seven of the 10 shRNA pools gave rise to 
detectable tumors. After two weeks, tumors were dissected and genomic DNA 
was extracted. To identify the candidate shRNAs, the shRNA region of the 
transduced virus was PCR amplified, cloned and sequenced (Gazin et al 2007). 
We recovered 41 independent shRNAs from the seven tumors (Table 2.2.1). 
To validate the candidates, single shRNAs directed against each gene 
were stably transduced into NIH 3T3 cells, and the knockdown (KD) cell lines 
were generated.  We tested the ability of the NIH 3T3 KD cells lines to form 
tumors in vivo following subcutaneous injection into nude mice. Figure 2.2.1.C 
shows that all 33 shRNAs promoted tumor formation, whereas a control non-
silencing shRNA, as expected, did not.  Quantitative real-time RT-PCR (qRT-
PCR) confirmed in all cases that expression of the target gene was decreased in 
the corresponding KD cell line (Figure 2.2.2).  
Of the 33 candidate TSGs, we could identify unambiguous human 
homologs in 28 cases, which are summarized in Table 2.2.2. These 28 human 
TSG candidates are involved in diverse biological processes including signal 
transduction, transcriptional regulation, cell growth/metabolism and DNA/RNA 
metabolism. Significantly, several of the genes such as IGF2R (Probst et al 2009, 
O’Gorman et al 1999; Motyka et al 2000; Nam et al 2010), SEMA3B (Castro-
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Rivera et al 2008; Rolny et al 2008; Nair et al 2007), and STK11 (also known as 
LKB1) (Mehenni et al 2005; Mehenni et al 2005) are well documented TSGs, 
validating the overall experimental strategy. 
 
Down-regulation of candidate TSGs in human lung squamous cell 
carcinoma samples 
To gain insight into the tumor types in which the candidate TSGs may play 
a role, we performed a series of cancer database searches. Analysis of the 28 
human TSG candidates using the NCBI SKY/M-FISH and CGH database 
(National Center for Biotechnology Information Spectral Karyotyping, Multiplex 
Fluorescence In Situ Hybridization and Comparative Genomic Hybridization; ref. 
23) revealed that all the genes have been found to harbor deletions in either one 
or both copies in multiple cancer types (Table 2.2.3). Furthermore, a search of 
the Oncomine cancer profiling database (Rhodes et al 2007) revealed that, with 
the exception of PKD1L3, all the candidate TSGs are significantly down-
regulated in a variety of cancers compared to normal tissues (Table 2.2.4). 
Notably, a large fraction of the candidate TSGs were down-regulated in 
lung cancers. To confirm and extend this finding, we analyzed expression of the 
28 genes in a series of human lung squamous cell carcinoma (hLSCC), lung 
adenocarcinoma and normal lung samples. The qRT-PCR analysis of 
Figure2.2.3 shows that 24 of the 28 candidate TSGs were down-regulated 
greater than 2-fold in ≥ 70% of the hLSCC samples analyzed. In several 
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instances, the candidate TSGs were down-regulated greater than 10-fold in all 
(or almost all) hLSCC samples (e.g., ANGPT1, FLNA, IGF2R, NME4, SEMA3B 
and STK11). Six genes were also down-regulated greater than 2-fold in ≥70% of 
the lung adenocarcinoma samples (Figure 2.2.4). 
 
Knocking down TSGs activates FGFR1 signaling pathway 
It has been shown that FGFR1 amplification is the most common genetic 
alteration in LSCC (~20%) (Weiss, 2010; Dutt, 2011).  In order to test whether 
knocking down TSGs can activate FGFR1 signaling pathway, we first knocked 
down our candidate TSGs using gene specific shRNAs in SA (small airway) cells, 
which are immortalized but non-transformed human lung small airway epithelia 
cells.  Then we examined the activation levels of FRS2, which is phosphorylated 
upon FGFR1 activation, in 24 TSG KD cell lines.  As shown in Figure 2.2.5, we 
found 17 out of 24 TSG KD cell lines increased pFRS2 to the level comparable to 
NCI-H520, while the total FRS2 expression levels were same as non-silencing 
control.  We further analyzed the phospho-FGFR1 and total-FGFR1 levels.  We 
found that knocking down 7 genes (FLNA, GAPVD1, MYD88, PIGH, PTGIS, 
SFRS9, SPAST) increased the total FGFR1 levels, and knocking down 5 genes 
(ANGPT1, DAPP1, FPR3, NME4, PTPN4) increased pFGFR1 levels without 
elevated tFGFR1.  However, Y653 phosphorylation of FGFR1 was not increased 
in FLNA and MYD88 KD cell lines, although the total FGFR1 is increased.  6 
genes (CDK5R1, DDX52, SDF2L1, SPOP, STK11, TXNRD1) increased pFRS2 
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level without elevated phospho- or total-FGFR1 levels.  It is known that pFRS2 
functions as a docking site for Grb2 and activates SOS and Gab1, and leads to 
activation of MAPK and AKT signaling pathways (Eswarakumar et al 2005; 
Altomare et al 2005).  We checked the levels of activated Akt and Erk, and found 
that, except PTGIS and SPAST, all TSGs KD cell lines with increased pFRS2 
levels had increased pErk levels. DAPP1 could affect both MAPK and AKT 
signaling pathways.  Four genes (IGF2R, LSM8, MAP1A, SEMA3B) inhibited 
pErk level independent of FGFR1 signaling. KD IGF2R didn’t activate FGFR 
signaling validated our results because IGF2R is a tyrosine kinase receptor 
independent of FGFR signaling.  Based on these results, we proposed a model 
in Figure 2.2.6 showing possible mechanisms that the TSGs function by 
negatively regulating FGFR1 signaling at different steps.  To further understand 
the relationship between our TSGs and FGFR1 signaling pathway, we knocked 
down FGFR1 in NCI-H520 cell line, using FGFR1 specific shRNA, and analyzed 
the mRNA levels of 24 TSGs.  We found de-repression of 3 genes (ANGPT1, 
DAPP1, TXNRD1) after FGFR1 knock down (Figure 2.2.7).  These results 
suggest that, these genes may have negative feedback effects on regulating 
FGFR1 signaling pathway.   
 
Knocking down TSGs induces transformation of lung epithelia cells 
Next, we tested whether knocking down TSGs has the same 
transformation function as FGFR1 amplification in lung epithelia cells.  First of all, 
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we tested whether overexpression FGFR1 could transform mouse and human 
cell lines.  As shown in Figure 2.2.8.A, 1 million FGFR1 overexpressed NIH3T3 
cells formed a tumor when subcutaneously injected into nude mice, while no 
tumor formed in the empty vector control.  This result is consistent with a 
previous report that FGFR1 can transform NIH3T3 (Hart et al 2000), and further 
confirmed that our TSG candidates from NIH3T3 screen might be related to 
FGFR1 oncogenic pathway.  Then we tested whether overexpression of FGFR1 
can transform human SA cells.  We found 5 million FGFR1 overexpressed SA 
cells formed a visible tumor in nude mice, while no tumor formed in the empty 
vector control (Figure 2.2.8.A).   
Then we want to test whether the activation of FGFR1 pathway by 
knocking down our TSG candidates can cause transformation of human SA lung 
cells.  In Figure 2.2.8.B, we performed in vitro soft agar colony formation assay, 
and found 14 out of 17 FGFR1 regulating genes and 4 FGFR1 signaling 
independent genes can form colonies in soft agar (Figure 2.2.8.B).  Then we 
injected knock down cell lines, that formed colonies in soft agar, into the flanks of 
nude mice and found they can all form tumors in vivo (Figure 2.2.8.C). Our 
results suggest that inhibiting these TSGs in normal cells can induce 
transformation by activating FGFR1 oncogenic signaling. 
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SA cells with TSGs knocking down are sensitive to FGFR inhibitor 
FGFR1 is a tyrosine kinase receptor.   Many small molecules have been 
generated to inhibit the FGFR1 tyrosine kinase (PD173074, ponatinib, BIBF1120 
etc) and they have been shown to inhibit cancer cell growth in vivo and in vitro 
(Weiss et al 2010; Joseph et al 2012; Hilberg et al 2008). Some of these 
inhibitors are in the process of clinical trials for cancer treatment.  Ponatinib is an 
oral tyrosine kinase inhibitor, and it is now in a pivotal phase II trial in patients 
with chronic myeloid leukemia (CML) and acute lymphoblasic leukemia (ALL), 
and it has been shown to inhibit kinase activity of FGFR1.  We wanted to test 
whether our TSGs KD cell lines are sensitive to Ponatinib.  We treated cells with 
500nM ponatinib for three days and found TSG KD cell lines that have increased 
pFGFR1 levels are sensitive to Ponatinib compared to non-silencing control, 
shown in Figure 2.2.9.A.  Our results suggest that the application of Ponatinib in 
lung squamous carcinoma might not be restricted to the patients with FGFR1 
amplification.  Lung cancer patients with repressed levels of these TSGs may 
also be good candidates for Ponatinib treatment.  To further confirm this, we first 
tested the Ponatinib sensitivity of A427, which is a lung squamous carcinoma cell 
line with normal copy of FGFR1.  A427 showed similar sensitivity to Ponatinib 
compare to FGFR1 amplified cell line NCI-H520, while a control cell line A549 
with normal level of FGFR1 showed more resistance (Figure 2.2.9.C).  Then, we 
compared the mRNA level of 24 TSG candidates in A427 and SA or HBEC cell 
lines. SA and HBEC are both immortalized but non-transformed lung epithelial 
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cells.  And we found 3 genes (STK11, MYD88, DAPP1) are highly repressed in 
A427 compare to SA or HBEC (Figure 2.2.9.B).  So we confirmed that patients 
with normal FGFR1 status but TSG deficient might be sensitive to FGFR1 
inhibitor.  Therefore, by examining the expression levels of TSGs in lung cancer 
patients, we could predict drug responsiveness and treatment outcome. 
 
Candidate TSG promoter hypermethylation in hLSCC samples  
To determine whether down-regulation of any of the candidate TSGs was 
a result of epigenetic silencing due to promoter hypermethylation, we performed 
comprehensive DNA methylation analysis to quantify promoter DNA methylation 
(Bibikova et al 2009). Genomic DNA was isolated from paired primary hLSCC 
and normal lung squamous cell samples from 18 individuals, subjected to 
bisulfite conversion, and hybridized to a genome-wide methylation array 
containing >27,500 individual CpG sites spanning ~14,500 promoters. To verify 
the quality of the methylation analysis, we first confirmed that well-established 
tumor suppressor genes, whose promoters are known to be hypermethylated in 
lung cancers.  PTGIS (Stearman et al 2007; Gray et al 2009), showed 
significantly higher promoter hypermethylation in lung cancer relative to normal 
samples. The methylation heat map of Figure 2.2.10.A and histogram of Figure 
2.2.10.B show that among the 26 candidate TSGs analyzed (GAPVD1 and 
PKD1L3 were absent from the array), nine displayed a statistically significant 
increase in promoter hypermethylation in lung cancer samples relative to normal 
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samples.  These results indicate that epigenetic silencing due to promoter 
hypermethylation represents one mechanism by which the candidate TSGs are 
down-regulated in human lung cancers. 
 
Over-expression of candidate TSGs inhibits growth of hLSCC cells 
To test whether ectopic expression of these candidate TSGs could inhibit 
cell proliferation, a representative subset were cloned into a retroviral vector co-
expressing green fluorescent protein (GFP) and transduced into NCI-H520 
hLSCC cells. Cells were selected with puromycin for 4 weeks and analyzed in a 
colony suppression assay. The results, shown in Figure 2.2.11.A and quantified 
in Figure 2.2.11.B, demonstrate that over-expression of all 16 genes tested 
reduced colony formation to varying extents. We then asked whether ectopic 
expression of the candidate TSGs could inhibit tumor growth in mouse 
xenografts. Retroviral vectors expressing 12 of the genes were transduced into 
NCI-H520 cells, and 24 h later GFP-positive cells were isolated by fluorescence-
activated cell sorting and injected subcutaneously into nude mice. Figure2.2.11.C 
shows that ectopic expression of all of the genes tested markedly suppressed 
tumor growth compared to the vector control.   
TSGs have been found to inhibit tumor growth through a variety of 
mechanisms including negatively regulating cell cycle progression, inducing 
senescence or promoting apoptosis (Sheer et al 2004). To gain insight into the 
mechanism-of-action of the candidate TSGs, GFP-positive NCI-H520 cells 
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ectopically expressing 16 of the TSG candidates were analyzed for their ability to 
induce apoptosis or senescence. We found that ectopic expression of 12 genes 
induced apoptosis in NCI-H520 cells as evidenced by cleavage of Caspase 3. 
(Figure 2.2.12.A and B). Furthermore, ectopic expression of six candidate TSGs 
induced senescence in NCI-H520 cells as evidenced by senescence-associated 
b-galactosidase staining (Figure 2.2.12.C and D). 
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Material and Methods 
Cell lines and culture 
NIH 3T3, K:Molv NIH 3T3 (referred to here as Kras NIH 3T3) and NCI-
H520 cells (ATCC) were grown in DMEM or RPMI medium, respectively, 
supplemented with 10% fetal bovine serum (Atlanta Biologicals) and 1X 
penicillin/streptomycin (Invitrogen).  SA cells are obtained from Scott Randell at 
University of North Carolina at Chapel Hill School of Medicine, cells were grown 
in BEGM medium from Lonza (CC-3170).   
 
Large-scale in vivo RNAi screen 
To determine the number of transformed cells that could potentially seed a 
tumor in our experimental system, 0, 100 or 1000 Kras-transformed NIH 3T3 
cells were mixed with non-transformed NIH 3T3 cells to achieve a final 
population of 1x106 cells, which were then injected into the flanks of nude mice 
(n=3). Tumor dimensions were measured every 1-2 days from the time of 
appearance of the tumors, and tumor volume was calculated using the formula 
π/4 x (length) x (width)2.  
The mouse shRNAmir library (release 2.16; Open Biosystems) was 
obtained through the University of Massachusetts Medical School (UMMS) RNAi 
Core Facility. Ten retroviral pools, each comprising ~6240 shRNA clones, were 
generated with titers of ~2.6x105 pfu/ml, as previously described (Gazin et al 
2004). Briefly, 1x106 NIH 3T3 cells were transduced at a multiplicity of infection 
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(MOI) of 0.2 with the retroviral stocks in 100 mm plates, and 2 days later selected 
for resistance to puromycin (1.5 µ g/ml) for 7 days. For each pool, 1x106 cells 
were then injected subcutaneously into the flank of a BALB/c nu/nu mouse 
(Taconic Farms). Tumors were excised and dissected, and genomic DNA was 
extracted. To identify the candidate shRNAs, the shRNA region of the transduced 
virus was PCR amplified, cloned and sequenced (Gazin et al 2004).  To validate 
the candidates, 2x106 NIH3T3 cells with individual shRNA KD (Table 2.2.5) were 
injected subcutaneously into nude mice (n=2); mice were sacrificed and 
photographed when the tumor size reached 1.5-2 cm. All animal experiments 
were performed in accordance with institutional and national guidelines and 
regulations and approved by the Institution Animal Care and Use Committee. 
 
In vitro transformation assay 
SA cells were infected with a lentivirus carrying an individual shRNA at 
high MOI.  1x104 cells were seeded in 6-well plates in soft agar.  Colonies are 
stained with crystal violet and scored after 4 weeks.  
 
Identification of human homologs 
Human homologs were identified using NCBI’s HomoloGene 
(www.ncbi.nlm.nih.gov/homologene). Human genes were considered to be 
homologs if they shared greater than 50% identity at the protein level with the 
mouse gene. 
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Analysis of gene expression in human lung cancer samples 
Total RNA from 10 normal lung, 10 adenocarcinoma and 27 hLSCC 
samples were obtained from the UMMS Cancer Center Tissue Bank. qRT-PCR 
was performed using primers listed in Table 2.2.6. 
 
Analysis of promoter methylation in human lung cancer samples 
Genomic DNA was extracted from ~200-300 mg of fresh-frozen primary 
hLSCC tissue and matching normal lung squamous cell tissue from 18 
individuals (obtained from The Prince Charles Hospital and University if 
Queensland Thoracic Research Center). High molecular-weight DNA was 
purified using the DNeasy Tissue Kit (Qiagen). Cleaned genomic DNA (1 µg) was 
bisulfite-converted using the EZ DNA Methylation Kit (Zymo Research), 
hybridized to multisample Illumina HumanMethylation27 v1.0 BeadChips. Images 
were processed, data extracted and control probes checked using the 
BeadStudio Methylation Module (Illumina) using default settings. All CpGs 
located on the X-chromosome were removed to avoid gender-specific bias. 
Percent methylation was calculated by measuring the intensity ratio of 
methylated to unmethylated DNA, giving a  β-value between 0 (100% 
methylation) and 1 (0% methylation). For each gene, the fold change was 
calculated for each individual by dividing the percent methylation in the tumor 
sample by the normal control. A gene with a fold change ≥1.5 was considered 
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hypermethylated (i.e., ≥50% increase in methylation) in hLSCC compared to 
normal lung, whereas a gene with a fold change <1.5 was considered to have no 
change in methylation status. To evaluate the significance of any observed 
number of hypermethylation events n for each gene, we estimated the probability 
of obtaining the value n or more in random data drawn according to a null model 
(i.e., individuals are independent and the hypermethylation rate is uniformly 
distributed among genes). Statistical analyses were performed using R (Ihaka 
and Gentleman 1996). The p-value for each gene was estimated based on 
binomial distribution. 
 
Ectopic expression of TSGs and analysis of tumor suppressor activity 
TSG cDNAs (Table 2.2.7) were cloned, by PCR (using primers listed in 
Table 2.2.6) followed by restriction enzyme digestion, into MSCV PIG (Puro-
IRES-GFP) (Addgene). For some genes, a 3xFlag tag sequence was 
incorporated into the primers for cloning in-frame with the target gene. Murine 
stem cell viruses (MSCVs) carrying TSGs were packaged in 293T cells and used 
to infect NCI-H520 cells. For the colony suppression assay, NCI-H520 cells 
(5x103) were plated in 6-well plates, infected with retroviruses at a multiplicity of 
infection (MOI) of 2 (or, in the case of IGF2R, transfected with a plasmid 
expressing IGF2R or empty vector), puromycin selected for 4 weeks and stained 
with crystal violet. For the mouse tumorigenesis assays, NCI-H520 cells were 
infected with retroviruses and 2 d later FACS sorted for GFP-positive cells. 2x106 
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viable GFP-positive cells were injected subcutaneously into nude mice, and 
tumor dimensions were measured and calculated every 3-4 d [using the formula 
(length x width2) x (π/4)]. For apoptosis assays, NCI-H520 cells were infected 
with retroviruses for 24 h, puromycin selected for 24 h, and recovered in fresh 
medium without puromycin for 3 d. Immunoblots were probed using an antibody 
against cleaved caspase-3 (Asp175) (Cell Signaling Technology) and quantified 
using Image J software (NIH). For cellular senescence assays, NCI-H520 cells 
were infected with retrovirus at a MOI of 2, and the medium was changed 24 h 
after infection. Cells were stained for β-galactosidase and visualized as 
previously described (Wajapeyee et al 2008). 
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DISCUSSION 
In this report, we have described an experimental strategy for the 
systematic identification of candidate TSGs. Based upon this approach, and 
subsequent functional analyses, we have identified human genes that have all 
the expected properties of TSGs including: promotion of tumorigenesis following 
inactivation, frequent deletion or down-regulation in human tumor samples, and 
inhibition of colony formation and/or tumor growth upon over-expression. 
Significantly, several of the genes we identified are well documented TSGs (e.g., 
STK11 and SEMA3B), thus validating the experimental approach.  Although we 
performed the primary screen by analyzing tumor formation in mice, a viable 
alternative would have been to first analyze growth in soft agar. We felt that a 
compelling advantage of the tumorigenesis assay is that it is a more stringent 
test of the transformed phenotype, and would therefore reduce the number of 
false positives obtained in the primary screen. However, an advantage of using 
the soft agar assay as a primary screen is that it is likely to be more economical. 
The relative advantages of the two approaches should be considered when 
designing other similar, large-scale screens. 
Our reconstruction experiment indicates that that, in principal, the design 
of the primary screen was sufficient to analyze all 62,400 shRNAs in the library. 
However, for several reasons we are reluctant to conclude that the screen was 
saturating and that all possible candidate TSGs were identified. In particular, 
transformed cells may have different growth rates depending upon the particular 
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shRNA present in the cell. Therefore, some shRNAs that induce transformation 
events may also cause cells to grow slowly and, as a consequence, those 
shRNAs may be relatively under-represented in the resulting tumors. In addition, 
we have found that not all shRNAs are equally efficacious and thus some 
candidate TSGs may be missed due to sub-optimal knockdown efficiency. 
Nonetheless, our experiments successfully identified a large number of 
candidate TSGs and therefore we were not compelled to search more 
exhaustively for further candidates. However, additional candidate TSGs could 
be identified by, for example, injecting each pool into more mice and obtaining a 
greater number of shRNA sequences from each tumor using either conventional 
approaches or massively parallel short sequencing. In any case, the possibility 
that there are additional candidate TSGs that were not identified in our screen 
does not diminish the fact that the approach successfully resulted in the 
discovery of a large number of new TSGs.  
 As discussed above, there have been several previous studies in which 
TSGs have been identified through in vivo RNAi screens using a limited 
collection of shRNAs that were selected based upon their previous implication in 
cancer (Bric et al, 2009; Meacham et al, 2009; Zender et al, 2008). The 
substantially smaller number of shRNAs screened in these studies increases the 
likelihood of complete coverage of the collection used. However, a significant 
disadvantage of this smaller scale approach is that the collection of shRNAs is 
biased and limited, precluding unexpected results from being obtained. 
  151 
 In this regard, several of the genes we found were previously 
unrecognized TSGs, with well-established roles in processes other than growth 
suppression. For example, MYD88 is a gene best known for its role in innate 
immunity (reviewed in Arancibia et al 2007) and SFRS9 encodes a pre-mRNA 
splicing factor (Screaton et al 1995).  Furthermore, the TSGs we identified that 
negatively regulate FGFR1 signaling could provide new hints for functional 
studies of these TSGs.  For example, PTPN4 is a known tyrosine phosphatase 
(Wu et al 2006) and can dephosphorylate the immunoreceptor tyrosine-based 
activation motifs (ITAMs).  We showed that knocking down PTPN4 increased 
phospho level of FGFR1, suggesting that FGFR1 might be a potential substrate 
of PTPN4.  GAPVD1 has been shown to mediate ubiquitination and degradation 
of EGFR (Xiong, 2007).  From our experiments, we showed that KD GAPVD1 
increased level of total FGFR1, therefore we think GAPVD1 might also mediate 
ubiquitination and degradation of FGFR1.  It is widely accepted that FGFR 
signals promote angiogenesis, and people found FGFR1 regulates angiogenesis 
through cytokines interleukin-4 and pleiotrophin in embryos.  However, little is 
known about FGFR1 induced angiogenesis in tumors.  We found that Angpt1, a 
known anti-angiogenesis protein, is repressed by FGFR1 overexpression and 
knocking down ANGPT1 can further activate FGFR1 signaling, thus form a 
negative feedback regulation of FGFR1.  It might be one of the mechanisms of 
angiogenesis in FGFR1 amplified lung cancer. 
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Our results highlight the power of unbiased, large-scale functional 
screening for cancer gene discovery. The shRNA screening approach we 
describe is a general strategy that can be used to discover new TSGs in any 
tumor type. A wide range of immortalized but non-transformed cell lines derived 
from different cell types are available and would presumably lead to the 
identification of distinct TSGs. Appropriate cell lines have been isolated from 
human tissue, such as MCF10A mammary epithelial cells, or experimentally 
derived from primary human cells using defined oncogenes (see, for examples, 
Hahn et al 1999, Gupta et al 2005, Sato et al 2006, Radulovich et al 2008, Qian 
et al 2005). 
Figure 2.2.1 
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Figure 2.2.1. Large-scale shRNA screen for the 
identification of candidate TSGs. (A) Schematic 
summary of the screen. (B) 0, 100 or 1000 Kras-
transformed NIH 3T3 cells were mixed with non-
transformed NIH 3T3 cells to achieve a final population of 
1x106 cells, which were then injected into the flanks of 
nude mice (n=3) (C) Tumor formation assay. The NIH 3T3 
KD cell lines were subcutaneously injected into nude 
mice, and tumors were photographed at various time 
points following injection. 
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Figure 2.2.2 
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Figure 2.2.2. shRNA knock down dfficiency.  qRT-PCR 
analysis monitoring shRNA-mediated knockdown 
efficiency for each TSG (error bars represent SD, n=3). 
Values are given relative to expression of each gene 
following treatment with a non-silencing (NS) shRNA, 
which was arbitrarily set to 1.   
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Figure 2.2.3 
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Figure 2.2.3. Down-regulation of candidate TSGs in 
human lung squamous cell carcinoma (hLSCC) 
samples. qRT-PCR analysis monitoring expression of 
each TSG in 27 hLSCC samples (error bars represent 
SD, n=3). Values were normalized to the expression of 
the TSG in 10 normal lung samples, the average of which 
was set to 1. The red line indicates 2-fold down-
regulation. Asterisks indicate samples whose fold down-
regulation vastly exceeds that shown in the graph. 
Samples have been re-ordered from least to most down-
regulated gene.  
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Figure 2.2.4 
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Figure 2.2.4. Down-regulation of candidate TSGs in 
human lung adenocarcinoma samples. qRT-PCR 
analysis monitoring expression of each TSG in 10 human 
lung adenocarcinoma samples (error bars represent SD, 
n=3). Values were normalized to the expression of the 
TSG in 10 normal lung samples, the average of which 
was set to 1. The red line indicates 2-fold down-
regulation. 
160 
AB
C 
Figure 2.2.5 
161 
Figure 2.2.5.  Knocking down TSGs in Small Airway 
(SA) cell line activates FGFR signaling pathway.  (A) 
Western blots show the levels of key proteins in the 
FGFR1 signaling pathway after treatment with non-
silencing shRNA or shRNA targeting candidate TSGs.  
Genes labeled in red have increased pFRS2 level, which 
indicates activation of FGFR1 signaling pathway. (B,C) 
Western blots show the tFGFR1 and pFGFR1 levels of 
KD cell lines that activate FGFR1 signaling pathway.  
Genes labeled in red have increased tFGFR1 level.  
Genes labeled in green have increased pFGFR1 without 
increase tFGFR1 level. 
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Figure 2.2.6 
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ANGPT1, DAPP1, 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NME4, 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CDK5R1, 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Figure 2.2.6. Model of TSGs negatively regulating 
FGFR1 signaling. 7 genes (FLNA, GAPVD1, MYD88, 
PIGH, PTGIS, SFRS9, SPAST) inhibit total FGFR1 
levels; 5 genes (ANGPT1, DAPP1, FPR3, NME4, 
PTPN4) inhibit pFGFR1 levels without elevated tFGFR1.  
Y653 phosphorylation of FGFR1 was not increased in 
FLNA and MYD88 KD cell lines, although the total 
FGFR1 is increased; 6 genes (CDK5R1, DDX52, 
SDF2L1, SPOP, STK11, TXNRD1) inhibit pFRS2 levels 
without elevated phospho- or total-FGFR1 levels; Four 
genes (IGF2R, LSM8, MAP1A, SEMA3B) inhibit pErk 
level independent of FGFR1 signaling. 
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Candidate TSGs 
Figure 2.2.7. Candidate TSGs repressed by FGFR1 
signaling at the transcriptional level.  Three candidate 
TSGs are de-repressed after FGFR1 knock down in NCI-
H520, monitored by qRT-PCR. 
166 
0 
5 
10 
15 
20 
25 
30 
35 
Fo
ld
 in
cr
ea
se
 o
f c
ol
on
y 
nu
m
be
r c
om
pa
re
 to
 N
S
 
B  
A  Vector  FGFR1 OE 
NIH3T3 
SA 
FGFR1 pathway 
Figure 2.2.8 
167 
C
Figure 2.2.8. Knocking down TSGs induces 
transformation of lung epithelia cells.  (A) 1 million 
NIH3T3 cells overexpressing FGFR1 and 5 million SA 
cells overexpressing FGFR1 formed tumors when 
subcutaneously injected into the flank of nude mice, 
while no tumor formed in empty vector controls.  (B) In 
vitro soft agar colony formation assay showed 14 out of 
17 FGFR1 regulating genes and 4 FGFR1 signaling 
independent genes can form colonies in soft agar.  (C) 
KD cell lines that formed colonies in soft agar were 
injected into the flanks of nude mice and formed tumors 
in vivo. 
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Figure 2.2.9. SA cells with TSGs knocked down are sensi1ve 
to FGFR inhibitor.  (A) AQer treatment with 500nM ponaUnib 
for  three days,  TSG KD cell  lines  that have  increased pFGFR1 
levels (see ﬁgure 2.2.5) were sensiUve to PonaUnib compared 
to non‐silencing control.  (B) 3 genes  (STK11, MYD88, DAPP1) 
are  highly  repressed  in  A427  compared  to  SA  or  HBEC.  (C) 
A427  showed  similar  sensiUvity  to  PonaUnib  (500nM) 
compared  to  FGFR1  ampliﬁed  cell  line  NCI‐H520,  while  a 
control  cell  line  A549  with  normal  level  of  FGFR1  showed 
more resistance 
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Figure 2.2.10 
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Figure 2.2.10. Candidate TSG promoter 
hypermethylation in hLSCC samples. (A) Left, 
methylation heat map for candidate TSGs showing 
hypomethylation (red) or hypermethylation (green) in the 
tumor sample. Genes that are significantly 
hypermethylated (defined as a ≥50% increase in 
methylation) in tumor samples (p-value < 0.05) are 
indicated by an asterisk. Right, color key. (B) Percent of 
individuals with significant hypermethylation in nine 
candidate TSGs. The p-value for each gene is shown. 
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Figure 2.2.10 
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Figure 2.2.11. Over-expression of candidate TSGs 
inhibits growth of hLSCC cells. (A) Colony suppression 
assay. NCI-H520 cells infected with a retrovirus 
expressing each candidate TSG or empty vector were 
stained with crystal violet. (B) Quantification of the colony 
suppression assay shown in (A) (error bars represent SD, 
n=3). (C) Tumor formation assay. NCI-H520 cells 
ectopically expressing a TSG were injected 
subcutaneously into nude mice and tumor growth was 
monitored (error bars represent SD, n=3).  
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Figure 2.2.12 
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Figure 2.2.12. Mechanisms of candidate TSGs 
inhibiting growth of hLSCC cells. (A) Apoptosis assays. 
NCI-H520 cells ectopically expressing each TSG were 
analyzed by immunoblot for cleaved caspase 3. (B). 
Cleaved caspase 3 protein levels visualized on western 
blots were quantified and normalized to actin levels, and 
then to cleaved caspase 3 levels in the vector control, 
which was set to 1. The red line denotes a 2-fold 
increase. (C) Cellular senescence assays. NCI-H520 cells 
expressing each TSG were stained for senescence-
associated β-galactosidase.  (D) The percent positive 
cells was quantified by counting the blue stained cells 
(error bars represent SD, n=3).  The red line denotes a 2-
fold increase relative to the vector control. 
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Table 2.2.1. List of 41 shRNAs recovered from tumors. 
 
 
 
 
 
 
 
 
Pool 
number 
ShRNAs recovered from the tumor 
1 Dnajc12, Gapvd1, Mrps18c, Mtap1a, Sfrs9, Svs6, Zfp422 
2 Ddx52 
3 Angpt1, Cdk5r1, Dapp1, Efna3, Nme4, Nup205, Pkd1l3, Ptpn4, 
Spast, Stk11 
4 Flna, Fpr3, Gzma, Orc1l, Prl7a2, Gm11541, Sdf2l1, Sip1, 
Riken4632401L01 
6 Mad2l1, Slfn4 
8 Dhrs9, Pigh 
9 Cr1l, Igf2r, Lsm8, Myd88, Ptgis, Sema3b, Spop, Txnrd1, Wap, 
Gm5058 
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Table 2.2.2. List of 32 candidate TSGs that validate in colony formation and 
mouse tumorigenesis assays. 
 
Biological 
process 
Gene 
symbol 
Gene name Human 
homolog 
Cell signaling Angpt1 angiopoietin 1 ANGPT1 
 Dapp1 dual adaptor for phosphotyrosine and 3-
phosphoinositides 1 
DAPP1 
 Fpr3 formyl peptide receptor 3 FPR3 
 Gapvd1 GTPase activating protein and VPS9 domains 1 GAPVD1 
 Igf2r insulin-like growth factor 2 receptor IGF2R 
 Myd88 myeloid differentiation primary response gene 88 MYD88 
 Pkd1l3 polycystic kidney disease 1 like 3 PKD1L3 
 Prl7a2 prolactin family 7, subfamily a, member 2 – 
 Ptpn4 protein tyrosine phosphatase, non-receptor type 4 PTPN4 
 Stk11 serine/threonine kinase 11 STK11 
Cell 
growth/migration/ 
metabolism 
Cdk5r1 cyclin-dependent kinase 5, regulatory subunit 1 (p35) CDK5R1 
 Flna filamin, alpha FLNA 
 Mtap1a microtubule-associated protein 1 A MAP1A 
 Nme4 non-metastatic cells 4, protein expressed in NME4 
 Sema3b sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (emaphoring) 3B 
SEMA3B 
 Slfn4 schlafen 4 – 
 Spast spastin SPAST 
DNA/RNA 
metabolism 
Ddx52 DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 DDX52 
 Lsm8 LSM8 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
LSM8 
 Orc1l origin recognition complex, subunit 1-like (S. cerevisiae) ORC1L 
 Sfrs9 splicing factor, arginine/serine rich 9 SFRS9 
Immunity Cr1l complement component (3b/4b) receptor 1-like – 
 Gzma granzyme A GZMA 
Lipid metabolism Pigh phosphatidylinositol glycan anchor biosynthesis, class H PIGH 
 Ptgis prostaglandin I2 (prostacyclin) synthase PTGIS 
Nuclear transport Nup205 nucleoporin 205 NUP205 
Transcriptional 
regulation 
Spop speckle-type POZ protein SPOP 
 Zfp422 zinc finger protein 422 ZNF22 
Protein 
folding/export/ 
metabolism 
Dnajc12 DnaJ (Hsp40) homolog, subfamily C, member 12 DNAJC12 
 Sdf2l1 stromal cell-derived factor 2-like 1 SDF2L1 
 Txnrd1 thioredoxin reductase 1 TXNRD1 
Unknown Wap whey acidic protein – 
  179 
 
Table 2.2.3. Summary of NCBI SKY/MFISH & CGH data for candidate TSGs. 
    
     
 
 
 
 
 
Gene 
 
 
 
 
Chromosome 
location 
B
la
dd
er
 
B
ra
in
&
C
N
S
 
B
re
as
t 
C
er
vi
ca
l 
C
ol
or
ec
ta
l 
K
id
ne
y 
Le
uk
em
ia
 
Li
ve
r 
Lu
ng
 
Ly
m
ph
om
a 
M
el
an
om
a 
M
ye
lo
m
a 
O
va
ria
n 
P
an
cr
ea
tic
 
P
ro
st
at
e 
S
ar
co
m
a 
ANGPT1 8q22.3-q23                 
CDK5R1 17q11.2                 
DAPP1 4q25-q27                 
DDX52 17q21.1                 
DNAJC12 10q22.1                 
FLNA Xq28                 
FPR3 19q13.3-q13.4                 
GAPVD1 9q33.3                 
GZMA 5q11-q12                 
IGF2R 6q26                 
LSM8 7q31.1-q31.3                 
MAP1A 15q13-qter                 
MYD88 3p22                 
NME4 16p13.3                 
NUP205 7q33                 
ORC1L 1p32                 
PIGH 14q11-q24                 
PKD1L3 16q22.2                 
PTGIS 20q13.13                 
PTPN4 2q14.2                 
SDF2L1 22q11.21                 
SEMA3B 3p21.3                 
SFRS9 12q24.31                 
SPAST 2p24-p21                 
SPOP 17q21.33                 
STK11 19p13.3                 
TXNRD1 12q23-q24.1                 
ZNF22 10q11                 
 
 indicates a reported deletion of the gene in the cancer type.  
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Table 2.2.4. Summary of Oncomine data analysis querying whether 
candidate TSGs are down-regulated in cancer versus normal tissue. 
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ANGPT1                     
CDK5R1                     
DAPP1                     
DDX52                     
DNAJC12                     
FLNA                     
FPR3                     
GAPVD1                     
GZMA                     
IGF2R                     
LSM8                     
MAP1A                     
MYD88                     
NME4                     
NUP205                     
ORC1L                     
PIGH                     
PKD1L3                     
PTGIS                     
PTPN4                     
SDF2L1                     
SEMA3B                     
SFRS9                     
SPAST                     
SPOP                     
STK11                     
TXNRD1                     
ZNF22                     
 
 indicates one or more reports of significant down-regulation of the gene in 
cancer versus normal tissue. 
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Table 2.2.5. List of catalog numbers for shRNAs obtained from Open 
Biosystems. 
 
 Gene Catalog number for 1st 
shRNA 
Catalog number for 2nd 
shRNA 
Angpt1 RMM1766-96738501 RMM1766-96739079 
Cdk5r1 RMM1766-96739750 RMM1766-96738443 
Cr1l RMM1766-97042824 RMM3981-98063631 
Dapp1 RMM1766-96738885 RMM1766-96880910 
Ddx52 RHS1764-9687389 RMM1766-96889298 
Dnajc12 RMM1766-9106520 RMM1766-96743200 
Flna RMM1766-96741212 RMM1766-9352033 
Fpr3 RMM1766-96746297 RMM1766-98468326 
Gapvd1 RMM1766-9336338 RMM1766-9336322 
Gzma RMM1766-96745254 RMM1766-9106902 
Igf2r RMM1766-97044218 RMM1766-98467508 
Lsm8 RMM1766-97044512 RMM1766-96881489 
Mtap1a RMM1766-9341607 RMM1766-96874116 
Myd88 RMM1766-97042719 RMM3981-97065530 
Nme4 RMM1766-96740301 RMM1766-96740215 
Nup205 RMM1766-96873936 RMM1766-9355153 
Orc1l RMM1766-96744068 RMM1766-96744205 
Pigh RMM1766-96891459 RMM1766-96737813 
Pkd1l3 RMM1766-9353837 RMM1766-9354529 
Prl7a2 RMM1766-96744814 RMM3981-98069754 
Ptgis RMM1766-97042638 RMM1766-96738598 
Ptpn4 RMM1766-96740179 RMM1766-96740341 
Sdf2l1 RMM1766-96743359 RMM3981-99012961 
Sema3b RMM1766-97042710 RMM3981-9621999 
Sfrs9 RMM1766-9106052 RMM3981-97059906 
Slfn4 RMM1766-96878856 RMM1766-97043261 
Spast RMM1766-96737853 RMM1766-96871825 
Spop RMM1766-97044276 RMM3981-98497970 
Stk11 RMM1766-96740219 RMM3981-9591552 
Txnrd1 RMM1766-97042622 RMM1766-97042953 
Wap RMM1766-97043220 RMM1766-97044227 
Zfp422 RMM1766-9336451 RMM1766-96739222 
  182 
 
Table 2.2.6. List of primers used for quantitative real-time RT-PCR and for 
cloning TSGs. 
 
mGene Forward primer (5’   3’) Reverse primer (5’   3’) 
qRT-PCR   
Angpt1 (mouse) GTGCCGATTTCAGCACGAAG CCATGATTTTGTCCCGCAGT 
ANGPT1 (human) GGACAGCAGGAAAACAGAGC GGGCACATTTGCACATACAG 
Cdk5r1 (mouse) TCATGAGCTCCAAGATGCTG CCTGACCGCTCTCATTCTTC 
CDK5R1 (human) TGCTGACATGCCTGTACCTC TTGATGACAGAGAGGCAACG 
Cr1l (mouse) TGTCCGCCTTCAGTCTCTGC TGTTCTCATTTCACGTTGCTGCT 
Dapp1 (mouse) TGTGCAAAGACGGGAGTTGAA TCGGACGGTATCTTCTCCTTGA 
DAPP1 (human) CTCTGTGCAAAGACCGGAGT CCCTTGGTTGAGCTGTTTTC 
Ddx52 (mouse) CACAGTCCACAGCTTCAGAGCA TCCCCTATTCCCTGCTCTTCC 
DDX52 (human) TGCTAGCAAGAGGGATTGATT CCCTTATTCCCTGCTCTTCC 
Dnajc12 (mouse) TTCCCAGAGGAGGGCATCTC GTTCTGAGGGAGCGTCACCA 
DNAJC12 (human) TCTGGAATGTCACCCAGACA TCCTTTGCCTTCTGCAGTTT 
Flna (mouse) AAGGCCTGGGGCTAAGCAAG GCCCATGTGTTTCACCAGGA 
FLNA (human) CCAGAAGAGCAGCTTCACAG ACGTGCTTCACCAGGATCTC 
Fpr3 (mouse) TCTGTGTCCCCTGAATCTGGA TCCCAGCACACCAAGGAAGA 
FPR3 (human) GGGACTCTGGATTTTCACCA GTCACCCCAGAATGCAAAGT 
Gapvd1 (mouse) TGGCCAACGAGGACTCTGTC CTCCACGGCTGCTGTGAACT 
GAPVD1 (human) GCGGATGACTTTGTTCCTGT TGTGAACTGCATCCACCAAT 
Gzma (mouse) GTTGACTGCTGCCCACTGTA TGGTTCCTGGTTTCACATCA 
GZMA (human) CCTCCGAGGTGGAAGAGACT TTTCAAGGCCAAAGGAAGTG 
Igf2r (mouse) AGAAGAAGCTCGGGCGTGTC CTTGCCCGTCCTTGCCTAGT 
IGF2R (human) CCGACTGCCAGTACCTCTTC GTTCTGACAGCCCCTTGTG 
Lsm8 (mouse) CATGAGCGGGTGTTCAGCTC AGGCTCTGCTCGGATGTTCC 
LSM8 (human) CAGCTCTTCACAGGGGGTAG CTGCTCGAATATTCCCCAAA 
Mtap1a (mouse) TGGAAATGACCCTGCCAATG TGCTGCTGTTGCTCGTGTGT 
MAP1A (human) TCCAAAGGCCTAGTCAATGG CGGAAGAAGTCAAGGTCAGC 
Myd88 (mouse) TCCCAGTATCCTGCGGTTCA TCTGGCTCCGCATCAGTCTC 
MYD88 (human) GCACATGGGCACATACAGAC TAGCTGTTCCTGGGAGCTGT 
Nme4 (mouse) GGACAATCAGGGGCGACTTC ACCACCATCTGCCCAGTTCA 
NME4 (human) GACTTCAGCGTCCACATCAG CTGGAACCACAGCTGGATCT 
Nup205 (mouse) CGGAGAGTCGCTGCAAAAGA TTCCTGGACAGCCTCAGCAG 
NUP205 (human) TTTATTCTTTGGCGCCATCT GATTGGTTTCTGAGGCGAAG 
Orc1l (mouse) CCGTCGGTCAGGACTAGAGGA ACTGGGCTCCACCAGAAGGA 
ORC1L (human) GTCGATCAGGACTGGAGGAA CCATGGTCTCTGACATGGTG 
Pigh (mouse) TACTGAAGGAGCCGGGGAAG GCTGTGGCTTTCTGGTGTGC 
PIGH (human) CAGTGGAACCACATGGGATA TCTCCTGGCAGCTCCTGTAT 
Pkd1l3 (mouse) CAATCCTGGGCTCCCTTTTG GGTGCAGGCGGATTCCTAAC 
PKD1L3 (human) TGCAGCATCTCTGACTACCG GGACTGGGTCTAAAGCGAAA 
Prl7a2 (mouse) CAAAACTTGCAGAGCTTTTTGA CGGTGTATTCCACATTTCCTG 
Ptgis (mouse) AACCAGTGCCTGGGGAAGAG CTGGCTGCATCAGACCGAAG 
PTGIS (human) ACTGCCTGGGGAGGAGTTAT GATCTCCACATCTGCGTTGA 
Ptpn4 (mouse) CCTGGCCTGACCATGGAGTA CAATGAGACACATGGCAGTTTCC 
PTPN4 (human) GAGCCATGATGATCCAAACA CAAAGCCTTCTTCATAAACTTTCA 
Sdf2l1 (mouse) AACCTGCACACGCACCACTT TTGCCCAGAACATCGGACTG 
SDF2L1 (human GCACCTCTGTGTTCCTGTCA TTCCACGTATTGTGCGTGTT 
Sema3b (mouse) GCATGTGCAGTGGACCTTCC CAACCGCGACGCAAAGATAC 
SEMA3B (human) GGACCCAGGAAGGATAGAGG GGCTGCGAAAGATGGTAAAG 
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Sfrs9 (mouse) CGGAATGGGGATGGTTGAAT CAGACCGCGACCGTGAGTAG 
SFRS9 (human) ATATGCCCTGCGTAAACTGG AGCTGGTGCTTCTCTCAGGA 
Slfn4 (mouse) GAATGGGTGAAGCGCCAGAT TCTTGCAAGCCCAGATCCAA 
Spast (mouse) TGCAATCTGCTGGAGATGACAG TTTGGTAAGGACACATATACCCG
TTT 
SPAST (human) CACTGGGTCCTATCCGAGAA GCTGACGCTGCGTTTTATTT 
Spop (mouse) CTGACCTCCACAGCGCAGAT GGAAAGGGCACTGTGCTGAA 
SPOP (human) GCCCTCTGCAGTAACCTGTC TTGACTTCCACCCAGAGGTC 
Stk11 (mouse) GCAGCAAGGTGAAGCCAGAA CCAACGTCCCGAAGTGAGTG 
STK11 (human) CATGACTGTGGTGCCGTACT TGTGACTGGCCTCCTCTTCT 
Txnrd1 (mouse) AGCAGCTGGACAGCACCATC TCTTGGCAACAGCATCCACA 
TXNRD1 (human) AGTAGGTCCACATGCACACG TTTGATCAAGTTCAAGCACAAAA 
Wap (mouse) CCAGCGACCGTGAGTGTTCT TCCAGGAGTGAAGGGTCTTGC 
Zfp422 (mouse) CAGCCAAGGAAAAGCCTATG TTCTCGTCCACGTTCCTTCT 
ZNF22 (human) CTCTCATCTGAGGCAGCACA GAGACCAGCCACAGACTTCC 
Cloning   
ANGPT1 GGAAGATCTTCCATGACAGTTTT
CCTTTCCTTTG 
CCGCTCGAGCGGTCAAAAATCTA
AAGGTCGAATC 
CDK5R1 CCGCTCGAGCGGATGGGCACG
GTGCTGTCCCT 
CCGCTCGAGCGGTCACCGATCC
AGGCCTAGGA 
DAPP1 CCGCTCGAGCGGATGGGCAGA
GCAGAACTTCTA 
CCGCTCGAGCGGCTATTTAAAGA
TGAACGACCGAG 
DDX52 GGAAGATCTATGGACTACAAAG
ACCATGACGGTGATTATAAAGAT
CATGACATCGATTACAAGGATG
ACGATGACAAGATGGACGTCCA
CGATCTCTT 
CCGCTCGAGCGGTTAACTTTTGT
CTTCAAGAGCTA 
FPR3 GAAGATCTATGGACTACAAAGA
CCATGACGGTGATTATAAAGATC
ATGACATCGATTACAAGGATGA
CGATGACAAGATGGAAACCAAC
TTCTCCATT 
CCGCTCGAGCGGTCACATTGCTT
GTAACTCCGT 
GZMA GAAGATCTATGAGGAACTCCTAT
AGATT 
CCCTCGAGTTAAACTGCTCCCTT
GATAG 
IGF2R CCGCTCGAGCGGATGGGGGCC
GCCGCCGG 
CCGCTCGAGCGGTCAGATGTGTA
AGAGGTCCTCG 
LSM8 GGAAGATCTATGGACTACAAAG
ACCATGACGGTGATTATAAAGAT
CATGACATCGATTACAAGGATG
ACGATGACAAGATGACGTCCGC
TTTGGAGAA 
CCGCTCGAGCGGTCAGTGTGCT
ACAGAATTTAAA 
MYD88 GGAAGATCTTCCGAATTCCCGG
GATATCATGC 
GGAAGATCTTCCTCAGGGCAGG
GACAAGGCC 
PIGH GGAAGATCTTCCATGGAGGATG
AGCGGAGCTTT 
CCGCTCGAGCGGTCATGGGCTT
GTTGATGTGGC 
PTGIS GGAAGATCTTCCATGGCTTGGG
CCGCGCTC 
GGAAGATCTTCCTCATGGGCGGA
TGCGGTAG 
SDF2L1 GGAAGATCTTCCATGTGGAGCG
CGGGCCGC 
CCGCTCGAGCGGTCAGAGTTCAT
CGTGACCTGC 
SEMA3B CCGCTCGAGATGGACTACAAAG
ACCATGACGGTGATTATAAAGAT
CATGACATCGATTACAAGGATG
ACGATGACAAGATGAACTTCGT
GAAGTTGCTG 
CCGGAATTCTCACCAGTGCGTTG
CGCT 
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SFRS9 CCGCTCGAGATGGACTACAAAG
ACCATGACGGTGATTATAAAGAT
CATGACATCGATTACAAGGATG
ACGATGACAAGATGTCGGGCTG
GGCGGAC 
CCGGAATTCTCAGTAGGGCCTGA
AAGGAG 
SPOP GAAGATCTATGGACTACAAAGA
CCATGACGGTGATTATAAAGATC
ATGACATCGATTACAAGGATGA
CGATGACAAGATGTCAAGGGTT
CCAAGTCC 
CCGCTCGAGCGGTTAGGATTGCT
TCAGGCGTTT 
STK11 GGAAGATCTATGGACTACAAAG
ACCATGACGGTGATTATAAAGAT
CATGACATCGATTACAAGGATG
ACGATGACAAGATGGAGGTGGT
GGACCCG 
CCGCTCGAGCGGTCACTGCTGC
TTGCAGGCC 
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Table 2.2.7. Source and catalog numbers for human cDNAs used to clone 
TSGs.  
 
Gene  Source Catalog number 
ANGPT1 Open Biosystems EHS1001-99608061 
CDK5R1 Open Biosystems MHS1010-58341 
DAPP1 Open Biosystems MHS1010-7429735 
DDX52 Open Biosystems MHS1011-9199110 
DNAJC12 Open Biosystems MHS1010-58074 
FPR3 Open Biosystems MHS1010-98684799 
GZMA Open Biosystems MHS1011-76468 
IGF2R ATCC 95661 
LSM8 Open Biosystems MHS1011-60450 
MYD88 Open Biosystems MHS1010-73828 
NUP205 Open Biosystems EHS1001-99865050 
PIGH Open Biosystems MHS1011-60796 
PTGIS Open Biosystems MHS1010-98052790 
SDF2L1 Open Biosystems MHS4426-99240278 
SEMA3B Open Biosystems MHS1010-74089 
SFRS9 Open Biosystems MHS1010-98052451 
SPOP Open Biosystems MHS1010-57540 
STK11 Open Biosystems MHS1011-62254 
TXNRD1 Open Biosystems MHS1010-58057  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